PureCycle (PCT) 10-Q 12 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 10, 2022
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-40234
Entity Registrant Name	PureCycle Technologies, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	86-2293091
Entity Address, Address Line One	5950 Hazeltine National Drive,
Entity Address, Address Line Two	Suite 650
Entity Address, City or Town	Orlando
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32822
City Area Code	877
Local Phone Number	648-3565
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		163,232,226
Amendment Flag	false
Entity Central Index Key	0001830033
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Common Stock, par value $0.001 per share
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	PCT
Security Exchange Name	NASDAQ
Warrants, each exercisable for one share of common stock, $0.001 par value per share, at an exercise price of $11.50 per share
Entity Information [Line Items]
Title of 12(b) Security	Warrants, each exercisable for one share of common stock, $0.001 par value per share, at an exercise price of $11.50 per share
Trading Symbol	PCTTW
Security Exchange Name	NASDAQ
Units, each consisting of one share of common stock, $0.001 par value per share, and three quarters of one warrant
Entity Information [Line Items]
Title of 12(b) Security	Units, each consisting of one share of common stock, $0.001 par value per share, and three quarters of one warrant
Trading Symbol	PCTTU
Security Exchange Name	NASDAQ

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
CURRENT ASSETS
Cash	$ 198,169	$ 33,417
Debt securities available for sale	219,759	167,365
Restricted cash – current	100,210	141,855
Prepaid expenses and other current assets	3,191	2,712
Total current assets	521,329	345,349
Restricted cash – non-current	91,663	88,586
Prepaid expenses and other non-current assets	5,524	5,535
Operating lease right-of-use assets	13,953	0
Property, plant and equipment, net	266,305	225,214
TOTAL ASSETS	898,774	664,684
CURRENT LIABILITIES
Accounts payable	1,841	1,401
Accrued expenses	19,330	35,526
Accrued interest	6,127	1,532
Total current liabilities	27,298	38,459
NON-CURRENT LIABILITIES
Deferred revenue	5,000	5,000
Bonds payable	232,752	232,508
Warrant liability	55,876	6,113
Operating lease right-of-use liabilities	13,561	0
Other non-current liabilities	1,106	1,069
TOTAL LIABILITIES	335,593	283,149
COMMITMENT AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Common shares - $0.001 par value, 250,000 shares authorized; 163,234 and 127,647 shares issued and outstanding as of March 31, 2022 and December 31, 2021	163	128
Additional paid-in capital	746,806	539,423
Accumulated other comprehensive loss	(577)	(237)
Accumulated deficit	(183,211)	(157,779)
TOTAL STOCKHOLDERS' EQUITY	563,181	381,535
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 898,774	$ 664,684

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in usd per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	163,234,000	127,647,000
Common stock, shares outstanding (in shares)	163,234,000	127,647,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Costs and expenses
Operating costs	$ 4,048	$ 2,130
Research and development	339	547
Selling, general and administrative	14,747	7,624
Total operating costs and expenses	19,134	10,301
Interest expense	444	2,043
Change in fair value of warrants	5,835	13,621
Other income	19	109
Total other expense	6,298	15,773
Net loss	$ (25,432)	$ (26,074)
Loss per share
Basic (in usd per share)	$ (0.19)	$ (0.51)
Diluted (in usd per share)	$ (0.19)	$ (0.51)
Weighted average common shares
Basic (in shares)	133,244	51,223
Diluted (in shares)	133,244	51,223
Other comprehensive loss:
Unrealized loss on debt securities available for sale	$ (340)	$ 0
Total comprehensive loss	$ (25,772)	$ (26,074)

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Removal of beneficial conversion feature upon adoption of ASU 2020-06	Common stockCommon stock	Common stockClass A Common Units	Common stockClass C Profits Units	Preferred StockClass B Preferred Units	Preferred StockClass B-1 Preferred Units	Additional paid-in capital	Additional paid-in capitalRemoval of beneficial conversion feature upon adoption of ASU 2020-06	Accumulated other comprehensive loss	Accumulated deficit	Accumulated deficitRemoval of beneficial conversion feature upon adoption of ASU 2020-06
Beginning balance (in shares) at Dec. 31, 2020			0	37,998,000	6,711,000	20,628,000	16,322,000
Beginning balance at Dec. 31, 2020	$ 111,749	$ (30,638)	$ 0	$ 38	$ 7	$ 21	$ 16	$ 192,381	$ (31,075)	$ 0	$ (80,714)	$ 437
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of units upon vesting of Legacy PCT profits interests (in shares)	0				116,000
Issuance of units upon vesting of Legacy PCT profits interests	$ 239							239
Redemption of vested profit units (in shares)					(5,000)
Redemption of vested profit units	(36)							(36)
Merger Recapitalization (in shares)			81,754,000	37,998,000	6,822,000	20,628,000	16,322,000
Merger Recapitalization	0		$ 82	$ (38)	$ (7)	$ (21)	$ (16)
ROCH Shares Recapitalized, Net of Redemptions, Warrant Liability and Issuance Costs of $28.0 million (in shares)			34,823,000
ROCH Shares Recapitalized, Net of Redemptions, Warrant Liability and Issuance Costs of $28.0 million	293,966		$ 35					293,931
Issuance of restricted stock awards (in shares)			775,000
Issuance of restricted stock awards	0		$ 1					(1)
Forfeiture of restricted stock (in shares)			(3,000)
Forfeiture of restricted stock	0		$ (1)					1
Reclassification of redeemable warrant to liability	(33)							(33)
Equity based compensation	68							68
Net loss	(26,074)										(26,074)
Ending balance (in shares) at Mar. 31, 2021			117,349,000	0	0	0	0
Ending balance at Mar. 31, 2021	349,241		$ 117	$ 0	$ 0	$ 0	$ 0	455,475		0	(106,351)
Beginning balance (in shares) at Dec. 31, 2021			127,647,000	0	0	0	0
Beginning balance at Dec. 31, 2021	381,535		$ 128	$ 0	$ 0	$ 0	$ 0	539,423		(237)	(157,779)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)			35,714,000
Issuance of common stock	205,296		$ 35					205,261
Share repurchase (in shares)			(130,000)
Share repurchase	$ (1,049)							(1,049)
Issuance of units upon vesting of Legacy PCT profits interests (in shares)	0
Equity based compensation (in shares)			3,000
Equity based compensation	$ 3,171							3,171
Unrealized loss on available for sale debt securities	(340)									(340)
Net loss	(25,432)										(25,432)
Ending balance (in shares) at Mar. 31, 2022			163,234,000	0	0	0	0
Ending balance at Mar. 31, 2022	$ 563,181		$ 163	$ 0	$ 0	$ 0	$ 0	$ 746,806		$ (577)	$ (183,211)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Parenthetical) $ in Millions	3 Months Ended
	Mar. 31, 2021USD ($)
Statement of Stockholders' Equity [Abstract]
Issuance costs	$ 28

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (25,432)	$ (26,074)
Adjustments to reconcile net loss to net cash used in operating activities
Equity-based compensation	3,171	307
Fair value change of warrants	5,835	13,621
Depreciation expense	818	490
Amortization of debt issuance costs and debt discounts	244	841
Amortization of premium on debt securities	146	0
Operating lease amortization expense	287	0
Issuance costs attributable to warrants	0	109
Changes in operating assets and liabilities
Prepaid expenses and other current assets	(479)	(1,770)
Prepaid expenses and other non-current assets	11	(1,685)
Accounts payable	747	423
Accrued expenses	(2,503)	(13,037)
Accrued interest	324	1,207
Deferred revenue	0	5,000
Operating right-of-use liabilities	(93)	0
Net cash used in operating activities	(16,924)	(20,568)
Cash flows from investing activities
Construction of plant	(52,177)	(33,891)
Purchase of debt securities, available for sale	(98,070)	0
Sale and maturity of debt securities, available for sale	45,189	0
Net cash used in investing activities	(105,058)	(33,891)
Cash flows from financing activities
Proceeds from issuance of common stock	206,071	0
Proceeds from issuance of warrants	43,929	0
Payments to repurchase shares	(1,049)	0
Common stock issuance costs	(775)	0
Other (payments) proceeds from financing activities	(10)	55
Proceeds from ROCH and PIPE financing, net of issuance costs	0	298,461
Bond issuance costs	0	(4,067)
Convertible notes issuance costs	0	(480)
Net cash provided by financing activities	248,166	293,969
Net increase in cash and restricted cash	126,184	239,510
Cash and restricted cash, beginning of period	263,858	330,574
Cash and restricted cash, end of period	390,042	570,084
Non-cash investing activities
Additions to property, plant, and equipment in accrued expenses	13,918	16,437
Additions to property, plant, and equipment in accounts payable	329	0
Additions to property, plant, and equipment in accrued interest	4,271	4,270
Non-cash financing activities
Initial fair value of acquired warrant liability	$ 0	$ 4,604

ORGANIZATION

ORGANIZATION	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION	ORGANIZATION Formation and Organization PureCycle Technologies, Inc. (“PCT” or “Company”) is a Florida-based corporation focused on commercializing a patented purification recycling technology (the “Technology”), originally developed by The Procter & Gamble Company (“P&G”), for restoring waste polypropylene into resin, called ultra-pure recycled (“UPR”) resin, which has nearly identical properties and applicability for reuse as virgin polypropylene. PCT has a global license for the Technology from P&G. PCT’s goal is to create an important new segment of the global polypropylene market that will assist multinational entities in meeting their sustainability goals, providing consumers with polypropylene-based products that are sustainable, and reducing overall polypropylene waste in the world’s landfills and oceans. Business Combination On March 17, 2021, PureCycle consummated the previously announced business combination (“Business Combination”) by and among Roth CH Acquisition I Co., a Delaware corporation (“ROCH”), Roth CH Acquisition I Co. Parent Corp., a Delaware corporation and wholly owned direct subsidiary of ROCH (“ParentCo”), Roth CH Merger Sub LLC, a Delaware limited liability company and wholly owned direct subsidiary of Parent Co, Roth CH Merger Sub Corp., a Delaware corporation and wholly owned direct subsidiary of ParentCo and PureCycle Technologies LLC (“PCT LLC” or “Legacy PCT”) pursuant to the Agreement and Plan of Merger dated as of November 16, 2020, as amended from time to time (the “Merger Agreement”). Upon the completion of the Business Combination and the other transactions contemplated by the Merger Agreement (the “Transactions”, and such completion, the “Closing”), ROCH changed its name to PureCycle Technologies Holdings Corp. and became a wholly owned direct subsidiary of ParentCo, PCT LLC became a wholly owned direct subsidiary of PureCycle Technologies Holdings Corp. and a wholly owned indirect subsidiary of ParentCo, and ParentCo changed its name to PureCycle Technologies, Inc. The Company’s common stock, units and warrants are now listed on the Nasdaq Capital Market (“NASDAQ”) under the symbols “PCT,” “PCTTU” and “PCTTW,” respectively. In connection with the Business Combination, ROCH entered into subscription agreements with certain investors (the “PIPE Investors”), whereby it issued 25.0 million shares of common stock at $10.00 per share (the “PIPE Shares”) for an aggregate purchase price of $250.0 million (the “PIPE Financing”), which closed simultaneously with the consummation of the Business Combination. Upon the Closing of the Business Combination, the PIPE Investors were issued shares of the Company’s common stock. Legacy PCT unitholders will be issued up to 4.0 million additional shares of the Company’s common stock if certain conditions are met (“the Earnout”). The Legacy PCT unitholders will be entitled to 2.0 million shares if after six months after the Closing and prior to or as of the third anniversary of the Closing, the closing price of the common stock is greater than or equal to $18.00 over any 20 trading days within any 30-trading day period. The Legacy PCT unitholders will be entitled to 2.0 million shares upon the commercial-scale plant in Ironton, Ohio (the “Ohio Phase II Facility”) becoming operational, as certified by Leidos Engineering, LLC (“Leidos”), an independent engineering firm, in accordance with criteria established in agreements in connection with construction of the plant. In connection with the Business Combination, the Company incurred direct and incremental costs of approximately $27.9 million related to the equity issuance, consisting primarily of investment banking and other professional fees, which were recorded to additional paid-in capital as a reduction of proceeds. The Company incurred approximately $5.2 million of expenses primarily related to advisory, legal, and accounting fees in conjunction with the Business Combination. Of this, $3.2 million was recorded in general and administrative expenses on the consolidated statement of comprehensive loss for the three months ended March 31, 2021. Unless the context otherwise requires, “Registrant,” “PureCycle,” “Company,” “PCT,” “we,” “us,” and “our” refer to PureCycle Technologies, Inc., and its subsidiaries at and after the Closing and give effect to the Closing. “Legacy PCT”, “ROCH” and “ParentCo” refer to PureCycle Technologies LLC, ROCH and ParentCo, respectively, prior to the Closing. The aggregate consideration for the Business Combination was $1,156.9 million, payable in the form of shares of the ParentCo Common Stock and assumed indebtedness. The following summarizes the merger consideration (in thousands except per share information): Total shares transferred 83,500 Value per share $ 10.00 Total Share Consideration $ 835,000 Assumed indebtedness Revenue Bonds 249,600 The Convertible Notes 60,000 Term Loan 314 Related Party Promissory Note 12,000 Total merger consideration $ 1,156,914 The following table reconciles the elements of the Business Combination to the condensed consolidated statement of cash flows for the three months ended March 31, 2021 (in thousands): Cash - ROCH Trust and cash (net of redemptions) $ 76,510 Cash - PIPE 250,000 Less transaction costs (28,049) Net Business Combination and PIPE financing $ 298,461 In addition to cash received by the Company at the Close of the Business Combination, the Company assumed a warrant liability from ROCH measured at $4.6 million at March 18, 2021. Refer to Note 6 – Warrants for further information. Private Placement Offering On March 7, 2022, the Company entered into subscription agreements (the “Subscription Agreements”) with certain investors (the “2022 PIPE Investors”), pursuant to which the Company agreed to sell to the Investors, in a private placement, shares of the Company’s common stock, par value $0.001 per share, and Series A warrants to purchase shares of Common Stock (the “Series A Warrants”) at a price of $7.00 per share of Common Stock and one-half (1/2) of one Series A Warrant (the “2022 PIPE Offering”). On March 17, 2022, the Company closed the 2022 PIPE Offering and issued to the 2022 PIPE Investors an aggregate of 35,714,272 shares of Common Stock and Series A Warrants to purchase an aggregate of 17,857,136 shares of Common Stock. The Company received approximately $250 million in gross proceeds from the 2022 PIPE Offering. The Company incurred approximately $0.8 million of expenses primarily related to advisory fees in conjunction with the 2022 PIPE Offering. Refer to Note 6 – Warrants for further information. Basis of Presentation The accompanying condensed consolidated interim financial statements include the accounts of the Company. The condensed consolidated interim financial statements are presented in U.S. Dollars. Certain information in footnote disclosures normally included in annual financial statements was condensed or omitted for the interim periods presented in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”). Intercompany balances and transactions were eliminated upon consolidation. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of the results to be expected for the entire year ending December 31, 2022. The accompanying condensed consolidated interim financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of management, necessary to present a fair statement of the results for the interim periods presented. Reclassifications Certain amounts in prior periods have been reclassified to conform with the report classifications of the three months ended March 31, 2022 and 2021. Potential Impact of COVID-19 on the Company’s Business The extent to which the COVID-19 pandemic and the restrictions resulting from the pandemic will continue to impact the Company’s business, financial condition or results of operations will depend on future developments, which are highly uncertain and cannot be accurately predicted. The Company has implemented certain policies and procedures to continue its operations in light of the COVID-19 pandemic and the restrictions resulting from the pandemic. Liquidity The Company has sustained recurring losses and negative cash flows from operations since its inception. As reflected in the accompanying condensed consolidated interim financial statements, the Company has not yet begun commercial operations and does not have any sources of revenue. As of March 31, 2022, and December 31, 2021, the Company had an unrestricted cash balance of $198.2 million and $33.4 million, respectively, working capital of $494.0 million and $306.9 million, respectively, and an accumulated deficit of $183.2 million and $157.8 million, respectively. For the three months ended March 31, 2022 and 2021, the Company incurred a net loss of $25.4 million and $26.1 million, respectively. Emerging Growth Company At March 31, 2022, we qualified as an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and we have taken and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. We have opted to take advantage of such extended transition period available to emerging growth companies which means that when a standard is issued or revised and it has different application dates for public or private companies, we can adopt the new or revised standard at the time private companies adopt the new or revised standard. Immaterial Corrections Related to Prior Periods We have identified immaterial corrections to prior periods related to capitalization of interest associated with the tax-exempt revenue bonds. We evaluated the effects of these corrections on the unaudited condensed consolidated financial statements for the three months ended March 31, 2021 individually and in the aggregate, in accordance with the guidance in ASC Topic 250, Accounting Changes and Error Corrections, ASC Topic 250-10-S99-1, Assessing Materiality, and ASC Topic 250-10-S99-2, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements. We have concluded that no period is materially

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less at date of inception to be cash and cash equivalents. As of March 31, 2022, the Company’s cash and cash equivalents balance represents cash and money market funds deposited with financial institutions, as well as commercial paper with maturities of 90 days or less at acquisition. As of December 31, 2021, the Company’s cash and cash equivalents balance represents cash and money market funds deposited with financial institutions. These balances may exceed federally insured limits; however, the Company believes the risk of loss is low. Investments The Company accounts for its investment in Debt Securities in accordance with ASC 320, Investments – Debt Securities . The fair value for fixed-rate debt securities is based on quoted market prices for the same or similar debt instruments and is classified as Level 2. All investment holdings as of March 31, 2022 and December 31, 2021 have been classified as Available for Sale. The Company classifies its Debt Securities investments as current assets as they are highly liquid and the related funds are available for use in current operations. Income Taxes To calculate the interim tax provision, at the end of each interim period the Company estimates the annual effective tax rate and applies that to its ordinary quarterly earnings. The effect of changes in the enacted tax laws or rates is recognized in the interim period in which the change occurs. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and judgments including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in other jurisdictions, permanent differences between book and tax amounts, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, additional information is obtained, or the tax environment changes. Furthermore, in December 2019, the FASB issued ASU No. 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The new guidance affects general principles within Topic 740, Income Taxes . The amendments of ASU 2019-12 are meant to simplify and reduce the cost of accounting for income taxes. The Company adopted the ASU during the first quarter of 2021 using a prospective approach. The adoption of the ASU did not have a material impact on the Company’s condensed consolidated financial statements. Warrants The Company evaluates all of its financial instruments, including issued warrants, to determine if such instruments are liability classified, pursuant to ASC 480 - Distinguishing Liabilities from Equity (“ASC 480”) or derivatives or contain features that qualify as embedded derivatives pursuant to ASC 815 – Derivatives and Hedging (“ASC 815”). The classification of instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Issuance costs incurred with the Business Combination that are attributable to liability classified warrants are expensed as incurred. Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”), to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. In July 2018, ASU 2018-10, Codification Improvements to Topic 84 2, Leases , was issued to provide more detailed guidance and additional clarification for implementing ASU 2016-02. Furthermore, in July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements , which provides an optional transition method in addition to the existing modified retrospective transition method by allowing a cumulative effect adjustment to the opening balance of retained earnings in the period of adoption. Furthermore, on June 3, 2020, the FASB deferred by one year the effective date of the new leases standard for private companies, private not-for-profits (“NFPs”) and public NFPs that have not yet issued (or made available for issuance) financial statements reflecting the new standard. The Company adopted Topic 842 and applicable technical updates as of January 1, 2022 using the modified retrospective transition method. See Note 14 for further details. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments (“ASU 2016-13”), which, together with subsequent amendments, amends the requirement on the measurement and recognition of expected credit losses for financial assets held. ASU 2016-13 is effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, with early adoption permitted. The Company is currently in the process of evaluating the effects of this pronouncement on the Company's financial statements and does not expect it to have a material impact on the consolidated financial statements.

NOTES PAYABLE AND DEBT INSTRUME

NOTES PAYABLE AND DEBT INSTRUMENTS	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
NOTES PAYABLE AND DEBT INSTRUMENTS	NOTES PAYABLE AND DEBT INSTRUMENTS Convertible Notes On October 6, 2020, Legacy PCT entered into a Senior Notes Purchase Agreement (the “Agreement”) with certain investors. The Agreement provides for the issuance of Senior Convertible Notes (the “Notes” or “Convertible Notes”), which have an interest rate of 5.875% and mature on October 15, 2022 (the “Maturity Date”). The initial closing took place on the date of the Indenture on October 7, 2020 (the “First Closing”), upon which $48.0 million in aggregate principal of Notes were issued to the Investors (“the Magnetar Investors”). The Agreement also includes an obligation for the Company to issue and sell, and for each of the Magnetar Investors to purchase, Notes in the principal amount of $12.0 million within 45 days after the Company enters into the Merger Agreement as defined in Note 1 (“Second Closing Obligation”). On December 29, 2020, the remaining Notes were purchased in accordance with the Agreement. The first and second interest payments of $1.7 million and $1.8 million, respectively, were due on April 15, 2021 and October 15, 2021, respectively, and were paid entirely in kind, which increased the principal amount of the Notes by $3.5 million (“PIK Interest”). The Notes were convertible through the Maturity Date at the option of the holder. During the fourth quarter of 2021, the entire $63.5 million principal balance of the Notes was converted into 9.2 million shares of common stock. The conversion increased common stock and Additional paid-in capital by $61.8 million, which represents the converted principal $63.5 million and forfeited interest of $0.1 million, offset by remaining capitalized issuance costs of $1.8 million. The following provides a summary of the interest expense of PCT’s convertible debt instruments (in thousands): Three months ended March 31, 2022 2021 Contractual interest expense $ — $ 881 Amortization of deferred financing costs — 641 Effective interest rate — % 9.1 % Revenue Bonds On October 7, 2020, the Southern Ohio Port Authority (“SOPA”) issued certain revenue bonds (“Bonds” or “Revenue Bonds”) pursuant to an Indenture of Trust dated as of October 1, 2020 (“Indenture”), between SOPA and UMB Bank, N.A., as trustee (“Trustee”), and loaned the proceeds from their sale to PureCycle: Ohio LLC, an Ohio limited liability company (“PCO”), pursuant to a loan agreement dated as of October 1, 2020 between SOPA and PCO (“Loan Agreement”), to be used to (i) acquire, construct and equip the Ironton Facility; (ii) fund a debt service reserve fund for the Exempt Facility Revenue Bonds (PureCycle Project), Tax-Exempt Series 2020A Bonds (“Series 2020A Bonds”); (iii) finance capitalized interest; and (iv) pay the costs of issuing the Bonds. The Bonds were offered in three series, including (i) Series 2020A Bonds; (ii) Subordinate Exempt Facility Revenue Bonds (PureCycle Project), Tax-Exempt Series 2020B; and (iii) Subordinate Exempt Facility Revenue Bonds (PureCycle Project), Taxable Series 2020C. The proceeds of the Bonds and certain equity contributions have been placed in various trust funds and non-interest-bearing accounts established and administered by the Trustee under the Indenture. Before each disbursement of amounts in the Project Fund held by the Trustee under the Indenture, PCO is required to submit to the Trustee a requisition for funds to be disbursed outlining the specified purpose of the disbursement and substantiating the expenditure. In addition, 100% of revenue attributable to the production of the Ironton Facility must be deposited into an operating revenue escrow fund held by U.S. Bank Trust Company, National Association, as escrow agent. Funds in the trust accounts and operating revenue escrow account will be disbursed by the Trustee when certain conditions are met, and will be used to pay costs and expenditures related to the development of the Ironton Facility, make required interest and principal payments (including sinking fund redemption amounts) and pay any premium, in certain circumstances required under the Indenture, to redeem the Bonds. At closing of the Bonds, Legacy PCT contributed $60.0 million in equity and executed a Guaranty of Completion dated as of October 1, 2020 (“Guaranty”) and PureCycle and certain affiliates contributed an additional $40.0 million million in equity upon the Closing of the Business Combination. Under the Guaranty, PureCycle funded a $50.0 million liquidity reserve for the Ironton Facility (“Liquidity Reserve”) and deposited that amount upon the Closing of the Business Combination in an escrow account held by U.S. Bank Trust Company, National Association, as escrow agent. In addition, the Guaranty requires that PureCycle maintain at least $75.0 million of cash on its balance sheet as of July 31, 2021 and $100.0 million of cash on its balance sheet as of January 31, 2022, in each case, including the Liquidity Reserve. The Company met these requirements and continues to maintain that cash balance at March 31, 2022. The Guaranty was amended and restated in May 2021 (“ARG”) to include a requirement, among others, that PureCycle replenish the Liquidity Reserve at the level of $50 million until completion of the Ironton Facility and the payment of all Project costs and until conditions relating to certain supply and offtake agreements have been met. Thereafter, the Liquidity Reserve amount will be reduced as provided in the ARG and PureCycle will not be required to replenish the reduced Liquidity Reserve. When all conditions to reducing the Liquidity Reserve to $25 million have been met, the reduced Liquidity Reserve without the obligation of replenishment will remain in place so long as any Series 2020A Bonds remain outstanding under the Indenture.

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
STOCKHOLDERS’ EQUITY	STOCKHOLDERS’ EQUITY Common Stock Holders of PCT common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. The holders do not have cumulative voting rights in the election of directors. Upon the Company’s liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of the Company’s common stock will be entitled to receive pro rata the Company’s remaining assets available for distribution. Holders of the Company’s common stock do not have preemptive, subscription, redemption or conversion rights. All shares of the Company’s common stock are fully paid and non-assessable. The Company is authorized to issue 250.0 million shares of common stock with a par value of $0.001. As of March 31, 2022, and December 31, 2021, 163.23 million and 127.65 million shares are issued and outstanding, respectively. Preferred Stock As of March 31, 2022, the Company is authorized to issue 25.0 million shares of preferred stock with a par value of $0.001, of which no shares are issued and outstanding.

EQUITY-BASED COMPENSATION

EQUITY-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
EQUITY-BASED COMPENSATION	EQUITY-BASED COMPENSATION 2021 Equity Incentive Plan On March 17, 2021, our stockholders approved the PureCycle Technologies, Inc. 2021 Equity and Incentive Compensation Plan (the “Plan”). The Plan provides for the grant of stock options, stock appreciation rights (“SARs”), restricted stock, restricted stock units (“RSUs”), performance shares, performance units, dividend equivalents, and certain other awards. As of March 31, 2022, approximately 8.28 million shares of common stock are reserved for issuance under the Plan. Restricted Stock Agreements RSUs issued pursuant to the Plan are time-based and vest over the period defined in each individual grant agreement or upon a change of control event as defined in the Plan. The Company recognizes compensation expense for the shares equal to the fair value of the equity-based compensation awards and is recognized on a straight-line basis over the vesting period of such awards. The fair value of the awards is equal to the fair value of the Company’s common stock at the date of grant. The Company has the option to repurchase all vested shares upon a stockholder’s termination of employment or service with the Company. For RSUs issued prior to approval of the Plan, the Company recognizes compensation expense for the shares equal to the fair value of the equity-based compensation awards and is recognized on a straight-line basis over the vesting period of such awards. Fair value of the RSUs is estimated on the date of grant using the Black-Scholes option-pricing model using the following assumptions: March 31, 2022 March 31, 2021 Expected annual dividend yield — % — % Expected volatility — % 49.1 % Risk-free rate of return — % 0.1 % Expected option term (years) 0 0.2 The expected term of the shares granted was determined based on the period of time the shares are expected to be outstanding. The risk-free rate was based on the U.S. Treasury yield curve in effect at the time of grant. The expected volatility was based on the Company’s capital structure and volatility of similar entities referred to as guideline companies. In determining similar entities, the Company considered industry, stage of life cycle, size and financial leverage. The dividend yield on the Company’s shares is assumed to be zero as the Company has not historically paid dividends. The fair value of the underlying Company shares for the three months ending March 31, 2021 was determined using an initial public offering scenario. On December 11, 2021, the Company and Michael Dee entered into a separation agreement (the “Separation Agreement”), which sets forth the terms of his transition and certain benefits he is eligible to receive, including continued vesting of 667.0 thousand RSU awards from his July 8, 2021 RSU Agreement, 50% of which vested on March 17, 2022 with the other 50% vesting upon commissioning of the Company’s first commercial plant. This was accounted for as an equity award modification under ASC 718, which resulted in adjustment of the award value to reflect the fair value at the modification date and acceleration of the recognition schedule to match his remaining service period, which ended on January 15, 2022 (the “Separation Date”). A summary of restricted stock activity for the three months ended March 31, 2022 and 2021 is as follows (in thousands except per share data): Number of RSU's Weighted average grant date fair value Weighted average remaining recognition period Non-vested at December 31, 2020 762 $ 1.39 2.12 Granted 143 11.90 Vested (116) 1.10 Forfeited (17) 3.13 Non-vested at March 31, 2021 772 $ 1.98 2.44 Number of RSU's Weighted average grant date fair value Weighted average remaining recognition period Non-vested at December 31, 2021 2,671 $ 14.33 3.38 Granted 980 7.24 Vested (438) 9.86 Forfeited (22) 17.50 Non-vested at March 31, 2022 3,191 $ 12.75 3.40 Equity-based compensation cost is recorded within the selling, general and administrative expenses in the condensed consolidated statements of comprehensive loss, and totaled approximately $3.4 million and $0.2 million for the three months ended March 31, 2022 and 2021, respectively. Stock Options The stock options issued pursuant to the Plan are time-based and vest over the period defined in each individual grant agreement or upon a change of control event as defined in the Plan. The Company recognizes compensation expense for the shares equal to the fair value of the equity-based compensation awards and is recognized on a straight-line basis over the vesting period of such awards. The fair value of the stock is estimated on the date of grant using the Black-Scholes option-pricing model using the following assumptions: March 31, 2022 March 31, 2021 Expected annual dividend yield — % — % Expected volatility — % 47.5 % Risk-free rate of return — % 0.7 % Expected option term (years) 0 4.5 The expected term of the shares granted is determined based on the period of time the shares are expected to be outstanding. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The expected volatility was based on the Company’s capital structure and volatility of similar entities referred to as guideline companies. In determining similar entities, the Company considered industry, stage of life cycle, size and financial leverage. The dividend yield on the Company’s shares is assumed to be zero as the Company has not historically paid dividends. The fair value of the underlying Company shares was determined using the Company’s closing stock price on the grant date. The Separation Agreement included provisions for accelerated vesting of 613.0 thousand Stock Options previously granted on March 17, 2021, which were scheduled to vest in equal installments on each anniversary date for three years after the date of grant and vested in full at the Separation Date. This was accounted for as an equity award modification under ASC 718, which resulted in adjustment of the award value to reflect the fair value at the modification date and acceleration of the recognition schedule to match his remaining service period, which ends on the Separation Date. A summary of stock option activity for the three months ended March 31, 2022 and 2021 is as follows (in thousands except per share data): Number of Options Weighted Average Exercise Price Weighted Balance, December 31, 2020 — $ — — Granted 613 28.90 7.00 Exercised — — — Forfeited — — — Balance, March 31, 2021 613 $ 28.90 7.00 Number of Options Weighted Average Exercise Price Weighted Balance, December 31, 2021 613 $ 28.90 6.21 Granted — — — Exercised — — — Forfeited — — — Balance, March 31, 2022 613 $ 28.90 4.80 Exercisable 613 — — Equity-based compensation cost is recorded within the selling, general and administrative expenses within the condensed consolidated statements of comprehensive loss. The Company recorded a benefit of approximately $158 thousand for the three months ended March 31, 2022 due to fair value adjustments related to modification under the Separation Agreement, and expense of $68 thousand for the three months ended March 31, 2021. The weighted average grant-date fair values of options granted during the three months ended March 31, 2022 and 2021 were $0 and $11.41, respectively. There were no stock options exercised during 2022 or 2021. Performance-Based Restricted Stock Agreements The shares issued pursuant to the Performance-Based Restricted Stock Agreements vest depending on if the performance obligations are met. In general, the performance-based stock units (“Performance PSUs”) will be earned based on achievement of pre-established financial and operational performance objectives and will vest on the date the attainment of such performance objectives as determined by the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”), subject to the participant’s continued employment with the Company. The Company has also issued PSUs that vest if the market price of the Company’s common stock exceeds a defined target during the performance period (“Market PSUs”, together with the Performance PSUs, the “PSUs”). The Company issued 853 thousand and 0 PSUs for the three months ended March 31, 2022, and 2021, respectively. As of March 31, 2022, the performance-based provision has not been achieved for any of the outstanding performance-based award. The Company recognizes compensation expense for the Performance PSUs equal to the fair value of the equity-based compensation awards and is recognized on a straight-line basis over the vesting period of such awards as the Company has concluded the performance condition is probable to be met. The fair value of the awards is equal to the fair value of the Company’s common stock at the date of grant. The Separation Agreement included provisions for continued vesting of 200.0 thousand Market PSU awards from the July 8, 2021 PSU Agreement, which will vest if the market price of the Company’s common stock exceeds a defined target during the performance period. This was accounted for as an equity award modification under ASC 718. As the fair value of the award at the date of modification was less than the grant date fair value and all cost for these awards was recognized prior to the modification, there was no impact related to the modified awards. A summary of the PSU activity for the three months ended March 31, 2022 and 2021 is as follows (in thousands except per share data): Number of PSUs Weighted Average Exercise Price Weighted Balance, December 31, 2020 — $ — 0 Granted — — Vested — — Forfeited — — Balance, March 31, 2021 — $ — 0 Number of PSUs Weighted Average Exercise Price Weighted Balance, December 31, 2021 424 $ 18.65 2.00 Granted 853 7.24 Vested — — Forfeited (14) 19.33 Balance, March 31, 2022 1,263 $ 10.93 2.25 Equity-based compensation cost is recorded within the selling, general and administrative expenses within the consolidated statements of comprehensive loss and was not material for the three months ended March 31, 2022 and 2021, respectively.

WARRANTS

WARRANTS	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
WARRANTS	WARRANTS RTI Warrants RTI Global (“RTI”) holds warrants to purchase 971 thousand shares of PCT common stock. RTI can exercise these warrants as of March 17, 2022. The warrants expire on December 31, 2024. The Company determined the warrants are liability classified under ASC 480. Accordingly, the warrants were held at their initial fair value and will be remeasured at fair value at each subsequent reporting date with changes in the fair value presented in the statements of comprehensive loss. A summary of the RTI warrant activity for the three months ended March 31, 2022 and 2021 is as follows (in thousands, except per share data, as adjusted to show the effect of the reverse recapitalization as described in Note 1): Number of warrants Weighted average exercise price Weighted average grant date fair value Weighted average remaining contractual term (years) Outstanding at December 31, 2020 971 $ 5.56 $ 0.03 4.00 Granted — — — — Exercised — — — — Outstanding at March 31, 2021 971 $ 5.56 $ 0.03 3.75 Exercisable 971 Number of warrants Weighted average exercise price Weighted average grant date fair value Weighted average remaining contractual term (years) Outstanding at December 31, 2021 971 $ 5.56 $ 0.03 3.00 Granted — — — — Exercised — — — — Outstanding at March 31, 2022 971 $ 5.56 $ 0.03 2.75 Exercisable 971 The Company recognized $1.3 million of benefit for the three months ended March 31, 2022 and $15.0 million of expense for the three months ended March 31, 2021. Refer to Note 11 – Fair Value of Financial Instruments for further information. Public Warrants and Private Warrants The Company has outstanding public and private warrants which entitle each holder to exercise its warrants only for a whole number of shares of Common Stock. Each whole warrant entitles the registered holder to purchase one whole share of the Company’s Common Stock at a price of $11.50 per share at the later of the closing of the Business Combination or one year after ROCH’s initial public offering, provided that the Company has an effective registration statement under the Securities Act covering the shares of Common Stock issuable upon exercise of the warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. The warrants will expire five years after March 17, 2021, or earlier upon redemption or liquidation. The private warrants are identical to the public warrants, except that the private warrants and the common stock issuable upon exercise of the private warrants were not transferable, assignable or salable until after March 17, 2021, subject to certain limited exceptions. Additionally, the private warrants are non-redeemable so long as they are held by the initial holder or any of its permitted transferees. If the private warrants are held by someone other than the initial holder or its permitted transferees, the private warrants will be redeemable by the Company and exercisable by such holders on the same basis as the public warrants. The Company may redeem the outstanding warrants in whole, but not in part, at a price of $0.01 per warrant upon a minimum of 30 days’ prior written notice of redemption, if and only if the last sale price of the Company’s common stock equals or exceeds $18.00 per share for any 20-trading days within a 30-trading day period ending three The Company has classified the private warrants as a warrant liability as there is a provision within the warrant agreement that allows for private warrants to be exercised via a cashless exercise while held by the Sponsor and affiliates of the Sponsor, but would not be exercisable at any time on a cashless basis if transferred and held by another investor. Therefore, the Company will classify the private warrants as a liability pursuant to ASC 815 until the private warrants are transferred from the initial purchasers or any of their permitted transferees. There were approximately 5.7 million Public Warrants and 0.2 million Private Placement Warrants outstanding at March 31, 2022 and 2021. Refer to Note 11 – Fair Value of Financial Instruments for further information. Series A Warrants Upon the closing of the 2022 PIPE Offering, the Company issued approximately 17.9 million Series A Warrants to the 2022 PIPE Investors to purchase shares of the Company’s common stock. Each whole warrant entitles the registered holder to purchase one whole share of the Company’s Common Stock at a price of $11.50 per share any time after September 17, 2022 (the “Initial Exercise Date”), provided that the Company has an effective registration statement under the Securities Act covering the shares of Common Stock issuable upon exercise of the warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of Common Stock. The warrants will expire on March 17, 2026. The Company may redeem the outstanding Series A Warrants in whole, but not in part, at a price of $0.01 per warrant upon a minimum of 30 days’ prior written notice of redemption, if and only if the last sale price of the Company’s common stock equals or exceeds $18.00 per share for any 20-trading days within a 30-trading day period commencing after the Series A Warrants become exercisable and ending three The agreements governing the Series A Warrants (the “Series A Warrant Agreements”) provide for a Black Scholes value calculation (“Black Scholes Value”) in the event of certain transactions (“Fundamental Transactions”), which includes a floor on volatility utilized in the value calculation at 100% or greater. The Company has determined this provision introduces leverage to the holders of the Series A Warrants that could result in a value that would be greater than the settlement amount of a fixed-for-fixed option on the Company’s own equity shares. Therefore, the Company will classify the Series A Warrants as a liability pursuant to ASC 815. As of March 31, 2022, there were approximately 17.9 million Series A Warrants outstanding. Refer to Note 11 – Fair Value of Financial Instruments for further information.

NET LOSS PER SHARE

NET LOSS PER SHARE	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
NET LOSS PER SHARE	NET LOSS PER SHAREThe Company follows the two-class method when computing net loss per common share when shares are issued that meet the definition of participating securities. The two-class method requires income available to common shareholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed. The two-class method also requires losses for the period to be allocated between common and participating securities based on their respective rights if the participating security contractually participates in losses. As holders of participating securities do not have a contractual obligation to fund losses, undistributed net losses are not allocated to nonvested restricted stock for purposes of the loss per share calculation. Presented in the table below is a reconciliation of the numerator and denominator for the basic and diluted earnings per share (“EPS”) calculations for the three months ended March 31, 2022 and 2021 (in thousands, except per share data): Three months ended March 31, 2022 2021 Numerator: Net loss $ (25,432) $ (26,074) Denominator: Weighted average common shares outstanding, basic and diluted 133,244 51,223 Net loss per share attributable to common stockholder, basic and diluted $ (0.19) $ (0.51)

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	PROPERTY, PLANT AND EQUIPMENT Presented in the table below are the major classes of property, plant and equipment by category as of the below dates: As of March 31, 2022 (in thousands) Cost Accumulated Depreciation Net Book Value Building $ 12,029 $ 772 $ 11,257 Machinery and equipment 20,539 4,741 15,798 Leasehold Improvements 2,957 317 2,640 Fixtures and Furnishings 104 41 63 Land improvements 150 15 135 Land 1,150 — 1,150 Construction in process 235,262 — 235,262 Total property, plant and equipment $ 272,191 $ 5,886 $ 266,305 As of December 31, 2021 (in thousands) Cost Accumulated Net Book Value Building $ 12,029 $ 695 $ 11,334 Machinery and equipment 20,016 4,183 15,833 Leasehold Improvements 2,902 154 2,748 Fixtures and Furnishings 104 37 67 Land improvements 150 12 138 Land 1,150 — 1,150 Construction in process 193,944 — 193,944 Total property, plant and equipment $ 230,295 $ 5,081 $ 225,214

DEVELOPMENT PARTNER ARRANGEMENT

DEVELOPMENT PARTNER ARRANGEMENTS	3 Months Ended
	Mar. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transaction [Abstract]
DEVELOPMENT PARTNER ARRANGEMENTS	DEVELOPMENT PARTNER ARRANGEMENTS License Agreements On October 16, 2015, Legacy PCT entered into a patent license agreement with P&G (the “Original Patent License Agreement”). Legacy PCT and P&G entered into an Amended and Restated Patent License Agreement on July 28, 2020 (the “Amended and Restated Patent License Agreement”). PCT and P&G entered into a side letter agreement on February 12, 2021 amending certain provisions of the Amended and Restated License Agreement (the “Side Letter Agreement” and, together with the Original Patent License Agreement and the Amended and Restated Patent License Agreement, the “License Agreement”). The License Agreement outlines three phases with specific deliverables for each phase. During Phase 1 of the License Agreement, P&G provided Legacy PCT with up to one full-time employee to assist in the execution of Legacy PCT’s research and development activities. During Phase 2, P&G provided up to two full-time employees to assist in the execution of Legacy PCT’s research and development activities. In April 2019, Legacy PCT elected to enter into Phase 3 of the License Agreement and prepaid a royalty payment in the amount of $2.0 million, which will be reduced against future royalties payable as sales occur. Phase 3 of the License Agreement relates to the commercial manufacture period for the manufacture of the licensed product. This phase includes the construction of the first commercial plant for the manufacture of the licensed product, details on the commercial sales capacity and the pricing of the licensed product to P&G and to third parties. Where the Company has made royalty payments to its product development partners, the Company expenses such payments as incurred unless it has determined that is it probable that such prepaid royalties have future economic benefit to the Company. In such cases prepaid royalties will be reduced as royalties would otherwise be due to the partners. Effective January 1, 2021, the Company entered into an agreement with P&G to provide certain research assistance through June 30, 2021. Under the terms of the January agreement, the Company is obligated to pay P&G $0.5 million for such services. Effective July 1, 2021, the Company entered into a consulting agreement with P&G. The agreement will expire effective June 30, 2022. Under the terms of the agreement, we are obligated to pay P&G $0.1 million for certain research assistance. As of March 31, 2022 and December 31, 2021, the Company is in Phase 3 of the License Agreement and has recorded $2.0 million within prepaid expenses and other non-current assets in the condensed consolidated balance sheets. On November 13, 2019, Legacy PCT entered into a patent sublicense agreement with Impact Recycling Limited (“Impact”) through the term of the patents. The agreement outlines an initial license fee of $2.5 million and royalties on production using the license. In 2020, Legacy PCT paid $890 thousand of the initial license fee, and during the three months ended March 31, 2021, the Company paid the remaining $1.6 million of the initial fee. The initial license fee of $2.5 million is recorded in prepaid expenses and other non-current assets in the condensed consolidated balance sheets and will be ratably amortized over the term of the underlying patent using the straight-line method. In May 2021, the Company began using the technology covered by the Impact agreement and commenced amortization as of this date. Block and Release Agreement On June 23, 2020, Legacy PCT entered into a block and release agreement with Total Petrochemicals & Refining S.A./N.V. (“Total”). Upon execution of the agreement, Total made a prepayment consisting of a payment of $5.0 million for future receipt of resin consisting of recycled polypropylene (“recycled PP”). The prepayment was placed in an escrow account until the “release condition” of the Company closing the bond offering and overall capital funding of at least $370.0 million has occurred. After the Company successfully raised the required capital, the $5.0 million was released to the Company in 2021 and recorded as deferred revenue in the condensed consolidated balance sheets. Strategic Alliance Agreement On December 13, 2018, Legacy PCT entered into a strategic alliance agreement with Nestle Ltd. (“Nestle”), which expires on December 31, 2023. Upon execution of the agreement, Nestle committed to provide $1.0 million to fund further research and development efforts. The funding provided by Nestle may be convertible, in whole or in part, into a prepaid product purchase arrangement at Nestle’s option, upon the time of product delivery beginning in 2021. Additionally, because the research and development efforts were not successful as of December 31, 2020, up to 50% of the funding may be convertible into a 5-year term loan obligation, payable to Nestle at an interest rate equivalent to the U.S. prime rate. As of the issuance of these statements, Nestlé has not elected to convert any funding into a term loan. PCT received the funding from Nestle on January 8, 2019. The Company has recorded $1.0 million as a deferred research and development obligation within other non-current liabilities in the condensed consolidated balance sheets as of March 31, 2022 and December 31, 2021. Recognition related to the funding received will be deferred until it is probable that Nestle will not exercise their option. If the prepaid product purchase option is exercised, the obligation will be recognized as an adjustment to the transaction price of future product sales (e.g., net revenue presentation). If the option is not exercised, or in the case of development efforts not being successful, any amounts not converted to a loan obligation will be recognized as a reduction to research and development costs.

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXESThe Company has determined that any net deferred tax assets are not more likely than not to be realized in the future, and a full valuation allowance is required. In addition, the Company has determined that any current forecasted operations would result in federal and state income tax losses which are also not more likely than not to be realized. As a result, for the periods ended March 31, 2022 and 2021, the Company has reported tax expense of $0 and $0, respectively.Management has evaluated the Company’s tax positions and has determined that the Company has taken no uncertain tax positions that require adjustment to the condensed consolidated interim financial statements for the respective periods.

FAIR VALUE OF FINANCIAL INSTRUM

FAIR VALUE OF FINANCIAL INSTRUMENTS	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and sets out a fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). Inputs are broadly defined as assumptions market participants would use in pricing an asset or liability. Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories: Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 - Inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly, and fair value is determined through the use of models or other valuation methodologies Level 3 - Inputs are unobservable for the asset or liability and include situations where there is little, if any, market activity for the asset or liability. The inputs into the determination of fair value are based upon the best information in the circumstances and may require significant management judgment or estimation. Assets and liabilities measured and recorded at Fair Value on a recurring basis As of March 31, 2022 and December 31, 2021, the Company’s financial assets and liabilities measured and recorded at fair value on a recurring basis were classified within the fair value hierarchy as follows (in thousands): March 31, 2022 December 31, 2021 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Investments: Commercial paper, available for sale $ — $ 124,653 $ — $ 124,653 $ — $ 76,930 $ — $ 76,930 Corporate Bonds, available for sale — 89,308 — 89,308 — 84,588 — 84,588 Municipal bonds, available for sale — 5,798 — 5,798 — 5,847 — 5,847 Total investments $ — $ 219,759 $ — $ 219,759 $ — $ 167,365 $ — $ 167,365 Liabilities Warrant liability: RTI warrants $ — $ — $ 3,893 $ 3,893 $ — $ — $ 5,175 $ 5,175 Private warrants — — 733 733 — — 938 938 Series A warrants — 51,250 — 51,250 — — — — Total warrant liability $ — $ 51,250 $ 4,626 $ 55,876 $ — $ — $ 6,113 $ 6,113 Measurement of the Private Warrants The private warrants are measured at fair value on a recurring basis using a Black-Scholes model. The private warrants are classified as Level 3 and were valued using the following assumptions: March 31, 2022 December 31, 2021 Expected annual dividend yield — % — % Expected volatility 71.70 % 69.50 % Risk-free rate of return 2.42 % 1.14 % Expected option term (years) 3.97 4.22 The expected term of the warrants granted are determined based on the duration of time the warrants are expected to be outstanding. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The expected volatility was based on the Company’s capital structure and volatility of similar entities referred to as guideline companies. In determining similar entities, the Company considered industry, stage of life cycle, size and financial leverage. The dividend yield on the Company’s warrants is assumed to be zero as the Company has not historically paid dividends. The fair value of the underlying Company shares was determined using the Black-Scholes calculation. The aggregate values of the private warrants were $0.7 million and $0.9 million on March 31, 2022 and December 31, 2021, respectively. A summary of the private warrants activity from December 31, 2021 to March 31, 2022 is as follows: Fair value (Level 3) Balance at December 31, 2021 $ 938 Change in fair value (205) Balance at March 31, 2022 $ 733 Refer to Note 6 – Warrants for further information. Measurement of the RTI warrants Significant changes in any of the significant unobservable inputs in isolation would not result in a materially different fair value estimate. The interrelationship between these inputs is insignificant. The Company has determined its warrant to be a Level 3 fair value measurement and has remeasured using the Black-Scholes option pricing model to calculate its fair value using the following assumptions: March 31, 2022 December 31, 2021 Expected annual dividend yield — % — % Expected volatility 58.1 % 59.6 % Risk-free rate of return 2.39 % 0.97 % Expected option term (years) 2.75 3.0 The expected term of the warrants granted are determined based on the duration of time the warrants are expected to be outstanding. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The expected volatility was based on the Company’s capital structure and volatility of similar entities referred to as guideline companies. In determining similar entities, the Company considered industry, stage of life cycle, size and financial leverage. The dividend yield on the Company’s warrants is assumed to be zero as the Company has not historically paid dividends. The fair value of the underlying Company shares was determined using the Black-Scholes calculation. The Company has an option to repurchase the Warrants at any time. The maximum fair value of the Warrants is limited by the fair value of the repurchase option, which cannot exceed $15.0 million. Changes in Level 3 liabilities measured at fair value for three months ended March 31, 2022 are as follows (in thousands): Fair value Balance at December 31, 2021 $ 5,175 Change in fair value (1,282) Balance at March 31, 2022 $ 3,893 Measurement of the Series A Warrants The Series A Warrants meet the definition of derivative instruments and are measured at fair value on a recurring basis using the market price of the Company’s publicly traded warrants, with changes in fair value recorded in current earnings. The Company has determined the publicly traded warrants to be an appropriate proxy to value the Series A Warrants as both warrants have similar redemption features and the same exercise price. The Series A Warrants are classified as Level 2 for both initial measurement at issuance and subsequent measurement each period. The Series A Warrants were initially valued at $43.9 million upon closing of the 2022 PIPE Offering. The Company recognized $7.3 million of expense in change in warrant fair value in the condensed consolidated statement of comprehensive loss for the three months ended March 31, 2022. Assets and liabilities recorded at carrying value In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are subject to fair value measurements.

AVAILABLE-FOR-SALE INVESTMENTS

AVAILABLE-FOR-SALE INVESTMENTS	3 Months Ended
	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
AVAILABLE-FOR-SALE INVESTMENTS	AVAILABLE-FOR-SALE INVESTMENTS The Company classifies its investments in debt securities as available-for-sale. Debt securities are comprised of highly liquid investments with minimum “A” rated securities and, as of March 31, 2022, consist of corporate entity commercial paper and securities and municipal bonds. The debt securities are reported at fair value with unrealized gains or losses recorded in accumulated other comprehensive income in the condensed consolidated balance sheets. Refer to Note 11, "Fair Value of Financial Instruments," for information related to the fair value measurements and valuation methods utilized. The following table represents the Company’s available-for-sale investments by major security type as of March 31, 2022 and December 31, 2021 (in thousands): March 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Total Fair Value Commercial Paper $ 124,747 $ 1 $ (95) $ 124,653 Corporate Bonds 89,731 5 (428) 89,308 Municipal Bonds 5,858 — (60) 5,798 Total $ 220,336 $ 6 $ (583) $ 219,759 December 31, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Total Fair Value Commercial Paper $ 76,961 $ — $ (31) $ 76,930 Corporate Bonds 84,771 — (183) 84,588 Municipal Bonds 5,870 — (23) 5,847 Total $ 167,602 $ — $ (237) $ 167,365 The following table summarizes the fair value and amortized cost bases of the Company’s available-for-sale investments by contractual maturity of March 31, 2022 and December 31, 2021 (in thousands): March 31, 2022 December 31, 2021 Amortized Cost Fair Value Amortized Cost Fair Value Due within one year $ 180,970 $ 180,711 $ 117,164 $ 117,100 Due after one year through five years 39,366 39,048 50,438 50,265 Total $ 220,336 $ 219,759 $ 167,602 $ 167,365 Debt securities as of March 31, 2022 had an average remaining maturity of 0.5 years.

CONTINGENCIES

CONTINGENCIES	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
CONTINGENCIES	CONTINGENCIES Legal Proceedings PCT is subject to legal and regulatory actions that arise from time to time in the ordinary course of business. The assessment as to whether a loss is probable or reasonably possible, and as to whether such loss or a range of such loss is estimable, often involves significant judgment about future events, and the outcome of litigation is inherently uncertain. Other than as described below, there is no material pending or threatened litigation against PCT that remains outstanding as of March 31, 2022. Regulatory Investigations On or around September 30, 2021, the SEC issued an investigative subpoena to PCT’s Chief Executive Officer requesting testimony in connection with a non-public, fact-finding investigation of the Company. The investigation pertains to, among other things, statements made in connection with PCT’s technology, financial projections, key supply agreements, and management. PCT and its Chief Executive Officer intend to cooperate with the SEC’s subpoena and investigation. On April 26, 2022, the Company received correspondence from the SEC notifying the Company that the SEC concluded the SEC’s non-public fact-finding investigation without further action at this time. Shareholder Securities Litigation Beginning on or about May 11, 2021, two putative class action complaints were filed against PCT, certain senior members of management and others, asserting violations of federal securities laws under Section 10(b) and Section 20(a) of the Exchange Act. The complaints generally allege that the applicable defendants made false and/or misleading statements in press releases and public filings regarding the Technology, PCT’s business and PCT’s prospects. The first putative class action complaint was filed in the U.S. District Court for the Middle District of Florida by William C. Theodore against PCT and certain senior members of management (the “Theodore Lawsuit”). The second putative class action complaint was filed in the U.S. District Court for the Middle District of Florida by David Tennenbaum against PCT, certain senior members of management and others (the “Tennenbaum Lawsuit” and, together with the Theodore Lawsuit, the “Class Action Lawsuits”). On July 14, 2021, the court granted a motion to consolidate the Class Action Lawsuits and on July 27, 2021, Tennenbaum filed a motion to voluntarily dismiss his complaint without prejudice. On August 5, 2021, the Court entered an order appointing the Mariusz Ciecko and Robert Ciecko as Co-Lead Plaintiffs (“Lead Plaintiffs”) and Pomerantz LLP as Lead Counsel. On September 27, 2021, the Lead Plaintiffs filed a consolidated amended complaint. The consolidated amended complaint seeks to represent a class of investors who purchased or otherwise acquired PCT’s securities between November 16, 2020, and May 5, 2021, certification of the alleged class, as well as compensatory and punitive damages. The consolidated amended complaint relies on information included in a research report published by Hindenburg Research LLC. On November 12, 2021, PCT and the individual defendants affiliated with PCT (“PCT Defendants”) and Byron Roth each filed separate motions to dismiss Lead Plaintiffs’ amended complaint. On December 28, 2021, Lead Plaintiffs filed their brief in opposition to the PCT Defendants’ and Byron Roth’s motions to dismiss. On January 18, 2022, the PCT Defendants filed a reply to Lead Plaintiffs’ brief. The PCT Defendants intend to vigorously defend the Class Action Lawsuits. Given the stage of the litigation, PCT cannot reasonably estimate at this time whether there will be any loss, or if there is a loss, the possible range of loss, that may arise from the unresolved Class Action Lawsuits. Derivative Litigation On November 3, 2021, Byung-Gook Han, a purported PCT shareholder, derivatively and purportedly on behalf of PCT, filed a shareholder derivative action in the United States District Court for the District of Delaware (Byung-Gook Han v. Otworth et. al., Case No. 1:21-cv-01569-UNA) against certain senior members of PCT’s management, PCT’s directors and Byron Roth, who was subsequently dismissed (collectively, the “Individual Han Defendants”), alleging violations of Section 20(a) of the Exchange Act and breaches of fiduciary duties and bringing claims for unjust enrichment and waste of corporate assets (“Han Derivative Suit"). The Han Derivative Suit generally alleges that the Individual Han Defendants made materially false and misleading statements in press releases, webinars and other public filings regarding the Technology, PCT’s business, PCT’s prospects, and the background and experience of the Individual Han Defendants. The Han Derivative Suit seeks unspecified monetary damages, reform of the company's corporate governance and internal procedures, unspecified restitution from the Individual Han Defendants, and costs and fees associated with bringing the action. On January 19, 2022, the court in the Han Derivative Suit granted the parties’ joint stipulation to stay the Han Derivative Suit and administratively closed the matter pending the disposition of the motions to dismiss in the Class Action Lawsuits. Should the Han Derivative Suit be reopened in the future, the Individual Han Defendants intend to vigorously defend against the Han Derivative Suit. Given the stage of the litigation, PCT cannot reasonably estimate at this time whether there will be any loss, or if there is a loss, the possible range of loss, that may arise from the unresolved Han Derivative Suit. On January 27, 2022, Patrick Ayers, a purported PCT shareholder, derivatively and purportedly on behalf of PCT, filed a shareholder derivative action in the United States District Court of the District of Delaware, captioned Patrick Ayers v. Otworth et. al., Case No. 1:22-cv-00110, against certain members of PCT’s management, PCT’s directors and others (collectively, the “Individual Ayers Defendants), alleging violations of Section 20(a) of the Exchange Act and breaches of fiduciary duties, as well as claims for unjust enrichment, gross mismanagement, contribution, and indemnification (“Ayers Derivative Suit"). The Ayers Derivative Suit generally alleges that the Individual Ayers Defendants made materially false and misleading statements in press releases, webinars and other public filings regarding the Technology, PCT’s business, PCT’s prospects, and the background and experience of the Individual Ayers Defendants. The Ayers Derivative Suit seeks unspecified monetary damages, declaratory relief, unspecified disgorgement and restitution from the Individual Ayers Defendants, and costs and fees associated with bringing the action. At this stage of the litigation, neither PCT nor the Individual Ayers Defendants have answered Ayers’ complaint, moved to dismiss the complaint, or otherwise responded to the complaint. On March 17, 2022, the court granted the parties’ joint stipulation to stay the Ayers Derivative Suit and administratively closed the matter pending the disposition of the motions to dismiss in the Class Action Lawsuits. The Individual Ayers Defendants intend to vigorously defend against the Ayers Derivative Suit. Given the stage of the litigation, PCT cannot reasonably estimate at this time whether there will be any loss, or if there is a loss, the possible range of loss, that may arise from the unresolved Ayers Derivative Suit. In the future, PCT may become party to additional legal matters and claims arising in the ordinary course of business. While PCT is unable to predict the outcome of the above or future matters, it does not believe, based upon currently available facts, that the ultimate resolution of any such pending matters will have a material adverse effect on its overall financial position, results of operations, or cash flows.

LEASES

LEASES	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
LEASES	LEASES The Company adopted ASC Topic 842, Leases , as of January 1, 2022 and has applied its transition provisions at the beginning of the period of adoption (i.e. on the effective date), and did not restate comparative periods. Under this transition provision, the Company has applied the legacy guidance under ASC Topic 840, Leases , including its disclosure requirements, in the comparative periods presented. Under ASC Topic 842, a lease is a contract, or part of a contract, that conveys the right to control the use of identified property, plant or equipment (i.e., an identified asset) for a period of time in exchange for consideration. The Company’s contracts determined to be, or contain, a lease include explicitly or implicitly identified assets where the Company has the right to substantially all of the economic benefits of the assets and has the ability to direct how and for what purpose the assets are used during the lease term. Leases are classified as either operating or financing. For operating leases, the Company has recognized a lease liability equal to the present value of the remaining lease payments, and a right of use asset equal to the lease liability, subject to certain adjustments, such as for prepaid rents. The Company used its incremental borrowing rate to determine the present value of the lease payments. The Company’s incremental borrowing rate is the rate of interest that it would have to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. The Company determined the incremental borrowing rates for its leases by applying its applicable borrowing rate, with adjustment as appropriate for lease currency and lease term. Upon adoption, the Company recognized right-of-use assets and lease liabilities for operating leases in the amount of $12.3 million and $12.7 million, respectively. The Company enters into contracts to lease real estate, equipment and vehicles. The Company’s most individually significant lease liability relates to a real estate lease with an initial contract lease term of 11 years. The Company’s most significant lease liabilities in aggregate value relate to real estate leases that have initial contract lease terms ranging from 1 to 11 years. Certain leases include renewal, termination or purchase options that were not deemed reasonably assured of exercise under ASC 840. Under ASC Topic 842, the lease term at the lease commencement date is determined based on the non-cancellable period for which the Company has the right to use the underlying asset, together with any periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option, and periods covered by an option to extend (or not to terminate) the lease in which the exercise of the option is controlled by the lessor. The Company considered a number of factors when evaluating whether the options in its lease contracts were reasonably certain of exercise, such as length of time before option exercise, expected value of the leased asset at the end of the initial lease term, importance of the lease to overall operations, costs to negotiate a new lease, and any contractual or economic penalties. Operating leases result in a straight-line lease expense, while finance leases result in a front-loaded expense pattern. The assets associated with financing leases have been included in property, plant and equipment in the condensed consolidated balance sheet. Depreciation on financing lease assets is included in operating costs on the condensed consolidated statement of comprehensive loss. The Company does not sublease any of its material leased assets to third parties and the Company is not party to any lease contracts with related parties. The Company’s lease agreements do not contain any residual value guarantees or restrictive covenants. ASC Topic 842 includes practical expedient and policy election choices. The Company elected the package of practical expedients available in the standard and as a result, did not reassess the lease classification of existing leases, did not reassess whether existing contracts are or contain leases and did not reassess the initial direct costs associated with existing leases. The Company did not elect the hindsight practical expedient, and so did not re-evaluate lease term for existing leases. The Company has made an accounting policy election not to recognize right of use assets and lease liabilities for leases with a lease term of 12 months or less, including renewal options that are reasonably certain to be exercised, that also do not include an option to purchase the underlying asset that is reasonably certain of exercise. Instead, lease payments for these leases are recognized as lease cost on a straight-line basis over the lease term. ASC Topic 842 includes a number of reassessment and re-measurement requirements for lessees based on certain triggering events or conditions, including whether a contract is or contains a lease, assessment of lease term and purchase options, measurement of lease payments, assessment of lease classification and assessment of the discount rate. The Company reviewed the reassessment and re-measurement requirements and did not identify any events or conditions during the quarter ended March 31, 2022 that required a reassessment or re-measurement. In addition, there were no impairment indicators identified during the quarter ended March 31, 2022 that required an impairment test for the Company’s right-of-use assets or other long-lived assets in accordance with ASC 360-10. Certain of the Company’s leases include variable lease costs to reimburse the lessor for real estate tax and insurance expenses, and certain non-lease components that transfer a distinct service to the Company, such as common area maintenance services. The Company has elected not to separate the accounting for lease components and non-lease components, for all classes of leased assets. The components of lease expense and supplemental cash flow information related to leases for the period are as follows: Three Months Ended March 31, 2022 Lease cost Operating lease cost $ 423 Short-term lease cost 103 Total lease cost $ 526 Other information Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 230 Right-of-use assets obtained in exchange for new operating lease liabilities $ 1,943 Weighted-average remaining lease term (in years) - operating leases 9.4 Discount rates Weighted-average discount rate - operating leases 4.0 % The supplemental balance sheet information related to leases for the period is as follows: March 31, 2022 Operating leases Operating lease right-of-use assets $ 13,953 Accrued expenses $ 1,012 Other long-term liabilities 13,561 Total operating lease liabilities $ 14,573 Maturities of the Company’s lease liabilities are as follows: Year Ending Operating Leases 2022 (April through December) $ 1,119 2023 1,824 2024 1,867 2025 1,918 2026 1,836 2027 1,856 Thereafter 7,391 Total lease payments 17,811 Less: Imputed interest (3,238) Present value of lease liabilities $ 14,573

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTSIn connection with the preparation of the condensed consolidated interim financial statements for the period ended March 31, 2022, management has evaluated events through May 12, 2022 to determine whether any events required recognition or disclosure in the condensed consolidated interim financial statements. The following subsequent events were identified through the date of these condensed consolidated interim financial statements:On April 26, 2022, the Company received correspondence from the SEC notifying the Company that the SEC concluded the SEC’s non-public fact-finding investigation without further action at this time.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Business Combination	Business Combination On March 17, 2021, PureCycle consummated the previously announced business combination (“Business Combination”) by and among Roth CH Acquisition I Co., a Delaware corporation (“ROCH”), Roth CH Acquisition I Co. Parent Corp., a Delaware corporation and wholly owned direct subsidiary of ROCH (“ParentCo”), Roth CH Merger Sub LLC, a Delaware limited liability company and wholly owned direct subsidiary of Parent Co, Roth CH Merger Sub Corp., a Delaware corporation and wholly owned direct subsidiary of ParentCo and PureCycle Technologies LLC (“PCT LLC” or “Legacy PCT”) pursuant to the Agreement and Plan of Merger dated as of November 16, 2020, as amended from time to time (the “Merger Agreement”).
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated interim financial statements include the accounts of the Company. The condensed consolidated interim financial statements are presented in U.S. Dollars. Certain information in footnote disclosures normally included in annual financial statements was condensed or omitted for the interim periods presented in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”). Intercompany
Reclassifications	Reclassifications Certain amounts in prior periods have been reclassified to conform with the report classifications of the three months ended March 31, 2022 and 2021.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less at date of inception to be cash and cash equivalents. As of March 31, 2022, the Company’s cash and cash equivalents balance represents cash and money market funds deposited with financial institutions, as well as commercial paper with maturities of 90 days or less at acquisition. As of December 31, 2021, the Company’s cash and cash equivalents balance represents cash and money market funds deposited with financial institutions. These balances may exceed federally insured limits; however, the Company believes the risk of loss is low.
Investments	Investments The Company accounts for its investment in Debt Securities in accordance with ASC 320, Investments – Debt Securities . The fair value for fixed-rate debt securities is based on quoted market prices for the same or similar debt instruments and is classified as Level 2. All investment holdings as of March 31, 2022 and December 31, 2021 have been classified as Available for Sale. The Company classifies its Debt Securities investments as current assets as they are highly liquid and the related funds are available for use in current operations.
Income Taxes	Income Taxes To calculate the interim tax provision, at the end of each interim period the Company estimates the annual effective tax rate and applies that to its ordinary quarterly earnings. The effect of changes in the enacted tax laws or rates is recognized in the interim period in which the change occurs. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and judgments including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in other jurisdictions, permanent differences between book and tax amounts, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, additional information is obtained, or the tax environment changes. Furthermore, in December 2019, the FASB issued ASU No. 2019-12, Income Taxes: Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The new guidance affects general principles within Topic 740, Income Taxes . The amendments of ASU 2019-12 are meant to simplify and reduce the cost of accounting for income taxes. The Company adopted the ASU during the first quarter of 2021 using a prospective approach. The adoption of the ASU did not have a material impact on the Company’s condensed consolidated financial statements.
Warrants	Warrants The Company evaluates all of its financial instruments, including issued warrants, to determine if such instruments are liability classified, pursuant to ASC 480 - Distinguishing Liabilities from Equity (“ASC 480”) or derivatives or contain features that qualify as embedded derivatives pursuant to ASC 815 – Derivatives and Hedging (“ASC 815”). The classification of instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Issuance costs incurred with the Business Combination that are attributable to liability classified warrants are expensed as incurred.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”), to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. In July 2018, ASU 2018-10, Codification Improvements to Topic 84 2, Leases , was issued to provide more detailed guidance and additional clarification for implementing ASU 2016-02. Furthermore, in July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements , which provides an optional transition method in addition to the existing modified retrospective transition method by allowing a cumulative effect adjustment to the opening balance of retained earnings in the period of adoption. Furthermore, on June 3, 2020, the FASB deferred by one year the effective date of the new leases standard for private companies, private not-for-profits (“NFPs”) and public NFPs that have not yet issued (or made available for issuance) financial statements reflecting the new standard. The Company adopted Topic 842 and applicable technical updates as of January 1, 2022 using the modified retrospective transition method. See Note 14 for further details. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments (“ASU 2016-13”), which, together with subsequent amendments, amends the requirement on the measurement and recognition of expected credit losses for financial assets held. ASU 2016-13 is effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, with early adoption permitted. The Company is currently in the process of evaluating the effects of this pronouncement on the Company's financial statements and does not expect it to have a material impact on the consolidated financial statements.

ORGANIZATION (Tables)

ORGANIZATION (Tables)	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Reverse Capitalization	The following summarizes the merger consideration (in thousands except per share information): Total shares transferred 83,500 Value per share $ 10.00 Total Share Consideration $ 835,000 Assumed indebtedness Revenue Bonds 249,600 The Convertible Notes 60,000 Term Loan 314 Related Party Promissory Note 12,000 Total merger consideration $ 1,156,914 The following table reconciles the elements of the Business Combination to the condensed consolidated statement of cash flows for the three months ended March 31, 2021 (in thousands): Cash - ROCH Trust and cash (net of redemptions) $ 76,510 Cash - PIPE 250,000 Less transaction costs (28,049) Net Business Combination and PIPE financing $ 298,461

NOTES PAYABLE AND DEBT INSTRU_2

NOTES PAYABLE AND DEBT INSTRUMENTS (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Summary of the Convertible Notes	The following provides a summary of the interest expense of PCT’s convertible debt instruments (in thousands): Three months ended March 31, 2022 2021 Contractual interest expense $ — $ 881 Amortization of deferred financing costs — 641 Effective interest rate — % 9.1 %

EQUITY-BASED COMPENSATION (Tabl

EQUITY-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Schedule of Equity-based Compensation, Valuation Assumptions	the RSUs is estimated on the date of grant using the Black-Scholes option-pricing model using the following assumptions: March 31, 2022 March 31, 2021 Expected annual dividend yield — % — % Expected volatility — % 49.1 % Risk-free rate of return — % 0.1 % Expected option term (years) 0 0.2 March 31, 2022 March 31, 2021 Expected annual dividend yield — % — % Expected volatility — % 47.5 % Risk-free rate of return — % 0.7 % Expected option term (years) 0 4.5
Schedule of Restricted Stock Activity	A summary of restricted stock activity for the three months ended March 31, 2022 and 2021 is as follows (in thousands except per share data): Number of RSU's Weighted average grant date fair value Weighted average remaining recognition period Non-vested at December 31, 2020 762 $ 1.39 2.12 Granted 143 11.90 Vested (116) 1.10 Forfeited (17) 3.13 Non-vested at March 31, 2021 772 $ 1.98 2.44 Number of RSU's Weighted average grant date fair value Weighted average remaining recognition period Non-vested at December 31, 2021 2,671 $ 14.33 3.38 Granted 980 7.24 Vested (438) 9.86 Forfeited (22) 17.50 Non-vested at March 31, 2022 3,191 $ 12.75 3.40
Schedule of Stock Option Activity	A summary of stock option activity for the three months ended March 31, 2022 and 2021 is as follows (in thousands except per share data): Number of Options Weighted Average Exercise Price Weighted Balance, December 31, 2020 — $ — — Granted 613 28.90 7.00 Exercised — — — Forfeited — — — Balance, March 31, 2021 613 $ 28.90 7.00 Number of Options Weighted Average Exercise Price Weighted Balance, December 31, 2021 613 $ 28.90 6.21 Granted — — — Exercised — — — Forfeited — — — Balance, March 31, 2022 613 $ 28.90 4.80 Exercisable 613 — —
Schedule of Performance-Based Restricted Stock Activity	A summary of the PSU activity for the three months ended March 31, 2022 and 2021 is as follows (in thousands except per share data): Number of PSUs Weighted Average Exercise Price Weighted Balance, December 31, 2020 — $ — 0 Granted — — Vested — — Forfeited — — Balance, March 31, 2021 — $ — 0 Number of PSUs Weighted Average Exercise Price Weighted Balance, December 31, 2021 424 $ 18.65 2.00 Granted 853 7.24 Vested — — Forfeited (14) 19.33 Balance, March 31, 2022 1,263 $ 10.93 2.25

WARRANTS (Tables)

WARRANTS (Tables)	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
Schedule of Warrant Activity	A summary of the RTI warrant activity for the three months ended March 31, 2022 and 2021 is as follows (in thousands, except per share data, as adjusted to show the effect of the reverse recapitalization as described in Note 1): Number of warrants Weighted average exercise price Weighted average grant date fair value Weighted average remaining contractual term (years) Outstanding at December 31, 2020 971 $ 5.56 $ 0.03 4.00 Granted — — — — Exercised — — — — Outstanding at March 31, 2021 971 $ 5.56 $ 0.03 3.75 Exercisable 971 Number of warrants Weighted average exercise price Weighted average grant date fair value Weighted average remaining contractual term (years) Outstanding at December 31, 2021 971 $ 5.56 $ 0.03 3.00 Granted — — — — Exercised — — — — Outstanding at March 31, 2022 971 $ 5.56 $ 0.03 2.75 Exercisable 971

NET LOSS PER SHARE (Tables)

NET LOSS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Summary of Net Income (Loss) per Share	Presented in the table below is a reconciliation of the numerator and denominator for the basic and diluted earnings per share (“EPS”) calculations for the three months ended March 31, 2022 and 2021 (in thousands, except per share data): Three months ended March 31, 2022 2021 Numerator: Net loss $ (25,432) $ (26,074) Denominator: Weighted average common shares outstanding, basic and diluted 133,244 51,223 Net loss per share attributable to common stockholder, basic and diluted $ (0.19) $ (0.51)

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	Presented in the table below are the major classes of property, plant and equipment by category as of the below dates: As of March 31, 2022 (in thousands) Cost Accumulated Depreciation Net Book Value Building $ 12,029 $ 772 $ 11,257 Machinery and equipment 20,539 4,741 15,798 Leasehold Improvements 2,957 317 2,640 Fixtures and Furnishings 104 41 63 Land improvements 150 15 135 Land 1,150 — 1,150 Construction in process 235,262 — 235,262 Total property, plant and equipment $ 272,191 $ 5,886 $ 266,305 As of December 31, 2021 (in thousands) Cost Accumulated Net Book Value Building $ 12,029 $ 695 $ 11,334 Machinery and equipment 20,016 4,183 15,833 Leasehold Improvements 2,902 154 2,748 Fixtures and Furnishings 104 37 67 Land improvements 150 12 138 Land 1,150 — 1,150 Construction in process 193,944 — 193,944 Total property, plant and equipment $ 230,295 $ 5,081 $ 225,214

FAIR VALUE OF FINANCIAL INSTR_2

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Summary of Assets and Liabilities Measurements on a Recurring Basis	As of March 31, 2022 and December 31, 2021, the Company’s financial assets and liabilities measured and recorded at fair value on a recurring basis were classified within the fair value hierarchy as follows (in thousands): March 31, 2022 December 31, 2021 Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Investments: Commercial paper, available for sale $ — $ 124,653 $ — $ 124,653 $ — $ 76,930 $ — $ 76,930 Corporate Bonds, available for sale — 89,308 — 89,308 — 84,588 — 84,588 Municipal bonds, available for sale — 5,798 — 5,798 — 5,847 — 5,847 Total investments $ — $ 219,759 $ — $ 219,759 $ — $ 167,365 $ — $ 167,365 Liabilities Warrant liability: RTI warrants $ — $ — $ 3,893 $ 3,893 $ — $ — $ 5,175 $ 5,175 Private warrants — — 733 733 — — 938 938 Series A warrants — 51,250 — 51,250 — — — — Total warrant liability $ — $ 51,250 $ 4,626 $ 55,876 $ — $ — $ 6,113 $ 6,113
RTI warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Measurement Inputs	The Company has determined its warrant to be a Level 3 fair value measurement and has remeasured using the Black-Scholes option pricing model to calculate its fair value using the following assumptions: March 31, 2022 December 31, 2021 Expected annual dividend yield — % — % Expected volatility 58.1 % 59.6 % Risk-free rate of return 2.39 % 0.97 % Expected option term (years) 2.75 3.0
Level 3 Liabilities Measured at Fair Value	Changes in Level 3 liabilities measured at fair value for three months ended March 31, 2022 are as follows (in thousands): Fair value Balance at December 31, 2021 $ 5,175 Change in fair value (1,282) Balance at March 31, 2022 $ 3,893
Private warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value Measurement Inputs	The private warrants are measured at fair value on a recurring basis using a Black-Scholes model. The private warrants are classified as Level 3 and were valued using the following assumptions: March 31, 2022 December 31, 2021 Expected annual dividend yield — % — % Expected volatility 71.70 % 69.50 % Risk-free rate of return 2.42 % 1.14 % Expected option term (years) 3.97 4.22
Level 3 Liabilities Measured at Fair Value	A summary of the private warrants activity from December 31, 2021 to March 31, 2022 is as follows: Fair value (Level 3) Balance at December 31, 2021 $ 938 Change in fair value (205) Balance at March 31, 2022 $ 733

AVAILABLE-FOR-SALE INVESTMENTS

AVAILABLE-FOR-SALE INVESTMENTS (Tables)	3 Months Ended
	Mar. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Schedule of Available-for-sale Investments by Major Security Type	The following table represents the Company’s available-for-sale investments by major security type as of March 31, 2022 and December 31, 2021 (in thousands): March 31, 2022 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Total Fair Value Commercial Paper $ 124,747 $ 1 $ (95) $ 124,653 Corporate Bonds 89,731 5 (428) 89,308 Municipal Bonds 5,858 — (60) 5,798 Total $ 220,336 $ 6 $ (583) $ 219,759 December 31, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Total Fair Value Commercial Paper $ 76,961 $ — $ (31) $ 76,930 Corporate Bonds 84,771 — (183) 84,588 Municipal Bonds 5,870 — (23) 5,847 Total $ 167,602 $ — $ (237) $ 167,365
Schedule of Fair Value and Amortized Cost Bases of Available-for-sale Investments by Maturity Date	The following table summarizes the fair value and amortized cost bases of the Company’s available-for-sale investments by contractual maturity of March 31, 2022 and December 31, 2021 (in thousands): March 31, 2022 December 31, 2021 Amortized Cost Fair Value Amortized Cost Fair Value Due within one year $ 180,970 $ 180,711 $ 117,164 $ 117,100 Due after one year through five years 39,366 39,048 50,438 50,265 Total $ 220,336 $ 219,759 $ 167,602 $ 167,365

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Schedule of Lease Expense and Supplemental Cash Flow Information	The components of lease expense and supplemental cash flow information related to leases for the period are as follows: Three Months Ended March 31, 2022 Lease cost Operating lease cost $ 423 Short-term lease cost 103 Total lease cost $ 526 Other information Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 230 Right-of-use assets obtained in exchange for new operating lease liabilities $ 1,943 Weighted-average remaining lease term (in years) - operating leases 9.4 Discount rates Weighted-average discount rate - operating leases 4.0 %
Schedule of Supplemental Balance Sheet Information Related to Leases	The supplemental balance sheet information related to leases for the period is as follows: March 31, 2022 Operating leases Operating lease right-of-use assets $ 13,953 Accrued expenses $ 1,012 Other long-term liabilities 13,561 Total operating lease liabilities $ 14,573
Lessee, Operating Lease, Liability, Maturity	Maturities of the Company’s lease liabilities are as follows: Year Ending Operating Leases 2022 (April through December) $ 1,119 2023 1,824 2024 1,867 2025 1,918 2026 1,836 2027 1,856 Thereafter 7,391 Total lease payments 17,811 Less: Imputed interest (3,238) Present value of lease liabilities $ 14,573

ORGANIZATION - Additional Infor

ORGANIZATION - Additional Information (Details) $ / shares in Units, $ in Thousands	Mar. 17, 2022USD ($)d$ / sharesshares	Mar. 31, 2021USD ($)	Mar. 17, 2021USD ($)d$ / sharesshares	Mar. 31, 2022USD ($)$ / shares	Mar. 31, 2021USD ($)	Mar. 07, 2022$ / shares	Dec. 31, 2021USD ($)$ / shares
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Shares issued (in shares) | shares			25,000,000
Price per share (in usd per share) | $ / shares			$ 10
Aggregate purchase price			$ 250,000
Maximum entitled shares issued (in shares) | shares			4,000,000
Shares entitled (in shares) | shares			2,000,000
Earnout period			6 months
Earnout stock price trigger (in usd per share) | $ / shares			$ 18
Earnout period, threshold trading days | d			20
Earnout period, threshold trading day period | d			30
Transaction costs incurred			$ 27,900
Advisory, legal, and accounting fees incurred	$ 800		5,200
General and administrative fees incurred					$ 3,200
Aggregate consideration			$ 1,156,914
Initial fair value of acquired warrant liability		$ 4,600		$ 0	4,604
Common stock, par value (in usd per share) | $ / shares				$ 0.001			$ 0.001
Cash				$ 198,169			$ 33,417
Working capital				494,000			306,900
Accumulated deficit				183,211			$ 157,779
Net loss				25,432	26,074
Interest expense				$ (444)	(2,043)
Revision of Prior Period, Error Correction, Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Increase in property, plant and equipment, net					4,100
Interest expense					$ 4,100
Series A warrants
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Earnout stock price trigger (in usd per share) | $ / shares	$ 18
Earnout period, threshold trading days | d	20
Earnout period, threshold trading day period | d	30
Warrants exercise price (in usd per share) | $ / shares	$ 11.50
Private Placement
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Aggregate purchase price	$ 250,000
Common stock, par value (in usd per share) | $ / shares						$ 0.001
Private Placement | Common stock
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Shares issued (in shares) | shares	35,714,272
Private Placement | Series A warrants
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Warrants exercise price (in usd per share) | $ / shares						$ 7
Percentage of warrant in offering						50.00%
Class of warrant or right, number of securities called by warrants or rights (in shares) | shares	17,857,136

ORGANIZATION - Merger Considera

ORGANIZATION - Merger Consideration (Details) $ / shares in Units, $ in Thousands	Mar. 17, 2021USD ($)$ / sharesshares
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Total shares transferred (in shares) | shares	83,500,000
Value per share (in usd per share) | $ / shares	$ 10
Total Share Consideration	$ 835,000
Revenue Bonds	249,600
The Convertible Notes	60,000
Term Loan	314
Related Party Promissory Note	12,000
Total merger consideration	$ 1,156,914

ORGANIZATION - Business Combina

ORGANIZATION - Business Combination in the Condensed Consolidated Statement of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash - ROCH Trust and cash (net of redemptions)		$ 76,510
Cash - PIPE		250,000
Less transaction costs		(28,049)
Net Business Combination and PIPE financing	$ 0	$ 298,461

ORGANIZATION - Immaterial Corre

ORGANIZATION - Immaterial Corrections Related to Prior Periods (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Decrease in interest expense	$ (444)	$ (2,043)
Revision of Prior Period, Error Correction, Adjustment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Increase in property, plant and equipment, net		4,100
Decrease in interest expense		$ 4,100

NOTES PAYABLE AND DEBT INSTRU_3

NOTES PAYABLE AND DEBT INSTRUMENTS - Additional Information (Details) shares in Millions	Oct. 15, 2021USD ($)	Apr. 15, 2021USD ($)	Oct. 06, 2020USD ($)	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)shares	Mar. 31, 2021USD ($)	Oct. 15, 2021USD ($)	Jan. 31, 2022USD ($)	Jul. 31, 2021USD ($)	Mar. 17, 2021USD ($)	Oct. 07, 2020USD ($)serie
Notes Payable
Debt Instrument [Line Items]
Escrow deposit											$ 50,000,000
Escrow deposit, stated conditions satisfied, amount				$ 25,000,000
Notes Payable | PureCycle Ohio LLC
Debt Instrument [Line Items]
Number of debt offering series | serie											3
Revenue Bonds
Debt Instrument [Line Items]
Operating revenue deposit requirement, percent											100.00%
Equity investments										$ 40,000,000	$ 60,000,000
Escrow deposit											50,000,000
Cash required to maintain								$ 100,000,000	$ 75,000,000
Interest expense				4,800,000		$ 4,800,000
Capitalized interest				$ 4,300,000		$ 4,300,000
Senior Notes Purchase Agreement | Convertible Debt
Debt Instrument [Line Items]
Interest rate, percent			5.875%
Principal amount											$ 48,000,000
Obligation to issue and sell			$ 12,000,000
Obligation to issue and sell, term			45 days
Paid-in-kind interest payment on notes	$ 1,800,000	$ 1,700,000					$ 3,500,000
Conversion of notes					$ 63,500,000
Redemption of vested profit units (in shares) | shares					9.2
Adjustments to additional paid in-capital for conversion of notes					$ 61,800,000
Forfeited interest on converted notes					100,000
Remaining capitalized issuance costs of converted notes					$ 1,800,000

NOTES PAYABLE AND DEBT INSTRU_4

NOTES PAYABLE AND DEBT INSTRUMENTS - Summary of Interest Expense of PCT's Convertible Debt (Details) - Convertible Debt - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Debt Instrument [Line Items]
Contractual interest expense	$ 0	$ 881
Amortization of deferred financing costs	$ 0	$ 641
Effective interest rate	0.00%	9.10%

STOCKHOLDERS_ EQUITY (Details)

STOCKHOLDERS’ EQUITY (Details)	Mar. 31, 2022vote$ / sharesshares	Dec. 31, 2021$ / sharesshares
Equity [Abstract]
Number of votes for each share held | vote	1
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, par value (in usd per share) | $ / shares	$ 0.001	$ 0.001
Common stock, shares outstanding (in shares)	163,234,000	127,647,000
Common stock, shares issued (in shares)	163,234,000	127,647,000
Preferred stock, shares authorized (in shares)	25,000,000
Preferred stock, par value (in usd per share) | $ / shares	$ 0.001
Preferred stock, shares outstanding (in shares)	0
Preferred stock, shares issued (in shares)	0

EQUITY-BASED COMPENSATION - Add

EQUITY-BASED COMPENSATION - Additional Information (Details) $ / shares in Units, $ in Thousands	Dec. 11, 2021shares	Mar. 31, 2022USD ($)$ / sharesshares	Mar. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2021shares	Dec. 31, 2020shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		0	613,000
Weighted average grant-date fair value (in usd per share) | $ / shares		$ 0	$ 11.41
Issuance of units upon vesting of Legacy PCT profits interests (in shares)		0	0
Former Chief Financial Officer | Share-Based Payment Arrangement, Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards subject to continuing vesting (in shares)		200,000
Former Chief Financial Officer | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)		613,000
Vesting period		3 years
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected annual dividend yield		0.00%	0.00%
Equity-based compensation cost | $		$ 3,400	$ 200
Awards outstanding (in shares)		3,191,000	772,000	2,671,000	762,000
Granted (in shares)		980,000	143,000
RSUs | Former Chief Financial Officer | Share-Based Compensation Arrangement, Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards subject to continuing vesting (in shares)	667,000
RSUs | Former Chief Financial Officer | Share-Based Compensation Arrangement, Restricted Stock Units | Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	0.50
RSUs | Former Chief Financial Officer | Share-Based Compensation Arrangement, Restricted Stock Units | Share-based Payment Arrangement, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting percentage	0.50
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected annual dividend yield		0.00%	0.00%
Equity-based compensation cost | $		$ (158)	$ 68
PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards outstanding (in shares)		1,263,000	0	424,000	0
Granted (in shares)		853,000	0
2020 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized (in shares)		8,280,000

EQUITY-BASED COMPENSATION - Res

EQUITY-BASED COMPENSATION - Restricted Stock Units, Valuation Assumptions (Details) - RSUs	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected annual dividend yield	0.00%	0.00%
Expected volatility	0.00%	49.10%
Risk-free rate of return	0.00%	0.10%
Expected option term (years)	0 years	2 months 12 days

EQUITY-BASED COMPENSATION - R_2

EQUITY-BASED COMPENSATION - Restricted Stock Activity (Details) - RSUs - $ / shares shares in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Number
Beginning balance (in shares)	2,671	762	762
Granted (in shares)	980	143
Vested (in shares)	(438)	(116)
Forfeited (in shares)	(22)	(17)
Ending balance (in shares)	3,191	772	2,671	762
Weighted average grant date fair value
Beginning balance (in usd per share)	$ 14.33	$ 1.39	$ 1.39
Granted (in usd per share)	7.24	11.90
Vested (in usd per share)	9.86	1.10
Forfeited (in usd per share)	17.50	3.13
Ending balance (in usd per share)	$ 12.75	$ 1.98	$ 14.33	$ 1.39
Weighted average remaining recognition period
Non-vested at the end of the period	3 years 4 months 24 days	2 years 5 months 8 days	3 years 4 months 17 days	2 years 1 month 13 days

EQUITY-BASED COMPENSATION - Sto

EQUITY-BASED COMPENSATION - Stock Options, Valuation Assumptions (Details) - Stock Options	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected annual dividend yield	0.00%	0.00%
Expected volatility	0.00%	47.50%
Risk-free rate of return	0.00%	0.70%
Expected option term (years)	0 years	4 years 6 months

EQUITY-BASED COMPENSATION - S_2

EQUITY-BASED COMPENSATION - Stock Option Activity (Details) - $ / shares	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Number of Options
Beginning balance (in shares)	613,000	0	0
Granted (in shares)	0	613,000
Exercised (in shares)	0	0
Forfeited (in shares)	0	0
Ending balance (in shares)	613,000	613,000	613,000
Exercisable (in shares)	613,000
Weighted Average Exercise Price
Beginning balance (in usd per share)	$ 28,900	$ 0	$ 0
Granted (in usd per share)	0	28,900
Exercised (in usd per share)	0	0
Forfeited (in usd per share)	0	0
Ending balance (in usd per share)	28,900	$ 28,900	$ 28,900
Exercisable (in usd per share)	$ 0
Additional Disclosures
Granted, Weighted Average Remaining Contractual Term (Years)		7 years
Weighted Average Remaining Contractual Term (Years)	4 years 9 months 18 days	7 years	6 years 2 months 15 days

EQUITY-BASED COMPENSATION - Per

EQUITY-BASED COMPENSATION - Performance-Based Restricted Stock Activity (Details) - PSUs - $ / shares shares in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Number
Beginning balance (in shares)	424	0	0
Granted (in shares)	853	0
Vested (in shares)	0	0
Forfeited (in shares)	(14)	0
Ending balance (in shares)	1,263	0	424	0
Weighted average grant date fair value
Beginning balance (in usd per share)	$ 18,650	$ 0	$ 0
Granted (in usd per share)	7,240	0
Vested (in usd per share)	0	0
Forfeited (in usd per share)	19,330	0
Ending balance (in usd per share)	$ 10,930	$ 0	$ 18,650	$ 0
Weighted average remaining recognition period
Non-vested at the end of the period	2 years 3 months	0 years	2 years	0 years

WARRANTS - Additional Informati

WARRANTS - Additional Information (Details) $ / shares in Units, $ in Millions	Mar. 17, 2022d$ / sharesshares	Mar. 17, 2021d$ / sharesshares	Nov. 20, 2020shares	Mar. 31, 2022USD ($)$ / sharesshares	Mar. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2021$ / sharesshares	Dec. 31, 2020$ / sharesshares
Class of Warrant or Right [Line Items]
Warrants redemption price (in usd per share) | $ / shares		$ 0.01
Warrants written notice of redemption threshold		30 days
Earnout stock price trigger (in usd per share) | $ / shares		$ 18
Earnout period, threshold trading days | d		20
Earnout period, threshold trading day period | d		30
Earnout period, business days prior to notice of redemption		3 days
Common stock
Class of Warrant or Right [Line Items]
Warrants issued (in shares)			971,000
Warrants, expense (benefit) recognized | $				$ (1.3)	$ 15
Warrants exercise price (in usd per share) | $ / shares				$ 5.56	$ 5.56	$ 5.56	$ 5.56
Weighted average remaining contractual term (years)				2 years 9 months	3 years 9 months	3 years	4 years
Warrants outstanding (in shares)				971,000	971,000	971,000	971,000
Public Warrants and Private Warrants
Class of Warrant or Right [Line Items]
Number of shares of common stock entitled to be purchased by each warrant (in shares)		1
Warrants exercise price (in usd per share) | $ / shares		$ 11.50
Weighted average remaining contractual term (years)		5 years
Public Warrants
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)				5,700,000	5,700,000
Private warrants
Class of Warrant or Right [Line Items]
Warrants outstanding (in shares)				200,000	200,000
Series A warrants
Class of Warrant or Right [Line Items]
Warrants issued (in shares)	17,900,000
Number of shares of common stock entitled to be purchased by each warrant (in shares)	1
Warrants exercise price (in usd per share) | $ / shares	$ 11.50
Warrants redemption price (in usd per share) | $ / shares	$ 0.01
Warrants written notice of redemption threshold	30 days
Earnout stock price trigger (in usd per share) | $ / shares	$ 18
Earnout period, threshold trading days | d	20
Earnout period, threshold trading day period | d	30
Warrants outstanding (in shares)				17,900,000
Earnout period, business days prior to notice of redemption	3 days
Series A warrants | Expected volatility
Class of Warrant or Right [Line Items]
Warrant, measurement input				1

WARRANTS - RTI Warrant Activity

WARRANTS - RTI Warrant Activity (Details) - Common stock - $ / shares	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Number of warrants
Beginning balance, Number of warrants (in shares)	971,000	971,000	971,000
Granted, Number of warrants (in shares)	0	0
Exercised, Number of warrants (in shares)	0	0
Ending balance, Number of warrants (in shares)	971,000	971,000	971,000	971,000
Exercisable, Number of warrants (in shares)	971,000	971,000
Weighted average exercise price
Beginning balance, Weighted average exercise price (in usd per share)	$ 5.56	$ 5.56	$ 5.56
Ending balance, Weighted average exercise price (in usd per share)	5.56	5.56	5.56	$ 5.56
Weighted average grant date fair value
Beginning balance, Weighted average grant date fair value (in usd per share)	0.03	0.03	0.03
Ending balance, Weighted average grant date fair value (in usd per share)	$ 0.03	$ 0.03	$ 0.03	$ 0.03
Additional disclosures
Weighted average remaining contractual term (years)	2 years 9 months	3 years 9 months	3 years	4 years

NET LOSS PER SHARE (Details)

NET LOSS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Numerator:
Net loss attributable to common stockholders, basic (in shares)	$ (25,432)	$ (26,074)
Net loss attributable to common stockholders, diluted (in shares)	$ (25,432)	$ (26,074)
Denominator:
Weighted average common shares outstanding, basic (in shares)	133,244	51,223
Weighted average common shares outstanding, diluted (in shares)	133,244	51,223
Net loss per share attributable to common stockholder, basic (in usd per share)	$ (0.19)	$ (0.51)
Net loss per share attributable to common stockholder, diluted (in usd per share)	$ (0.19)	$ (0.51)

PROPERTY, PLANT AND EQUIPMENT -

PROPERTY, PLANT AND EQUIPMENT - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Cost	$ 272,191	$ 230,295
Accumulated Depreciation	5,886	5,081
Net Book Value	266,305	225,214
Building
Property, Plant and Equipment [Line Items]
Cost	12,029	12,029
Accumulated Depreciation	772	695
Net Book Value	11,257	11,334
Machinery and equipment
Property, Plant and Equipment [Line Items]
Cost	20,539	20,016
Accumulated Depreciation	4,741	4,183
Net Book Value	15,798	15,833
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Cost	2,957	2,902
Accumulated Depreciation	317	154
Net Book Value	2,640	2,748
Fixtures and Furnishings
Property, Plant and Equipment [Line Items]
Cost	104	104
Accumulated Depreciation	41	37
Net Book Value	63	67
Land improvements
Property, Plant and Equipment [Line Items]
Cost	150	150
Accumulated Depreciation	15	12
Net Book Value	135	138
Land
Property, Plant and Equipment [Line Items]
Cost	1,150	1,150
Accumulated Depreciation	0	0
Net Book Value	1,150	1,150
Construction in process
Property, Plant and Equipment [Line Items]
Cost	235,262	193,944
Accumulated Depreciation	0	0
Net Book Value	$ 235,262	$ 193,944

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT - Additional information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Payments to Acquire Property, Plant, and Equipment [Abstract]
Depreciation expense	$ 818	$ 490

DEVELOPMENT PARTNER ARRANGEME_2

DEVELOPMENT PARTNER ARRANGEMENTS (Details) - Collaborative Arrangement, Transaction with Party to Collaborative Arrangement $ in Thousands	Jun. 23, 2020USD ($)	Nov. 13, 2019USD ($)	Dec. 13, 2018USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)	Jul. 01, 2021USD ($)	Jan. 01, 2021USD ($)	Apr. 30, 2019USD ($)	Oct. 16, 2015phaseemployee
P&G
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of phases outlined by research and development agreement | phase											3
Number of full-time employees to assist in execution of research and development activities, phase one | employee											1
Number of full-time employees to assist in execution of research and development activities, phase two | employee											2
Prepaid expenses and other non-current assets						$ 2,000	$ 2,000			$ 2,000
Obligation to pay for services								$ 100	$ 500
Impact
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Initial license fee		$ 2,500
Payment for license agreement				$ 1,600	$ 890
Total
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Prepayment for block and release agreement	$ 5,000
Block and release agreement, capital funding, minimum requirement	370,000
Escrow released	$ 5,000
Nestle
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Payment committed to fund further research and development			$ 1,000
Maximum funding convertible, percent			50.00%
Term loan obligation			5 years
Other non-current liabilities						$ 1,000	$ 1,000

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 0

FAIR VALUE OF FINANCIAL INSTR_3

FAIR VALUE OF FINANCIAL INSTRUMENTS - Summary of Liabilities Measurements on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 17, 2022	Dec. 31, 2021
Assets
Investments	$ 219,759		$ 167,365
Commercial paper, available for sale
Assets
Investments	124,653		76,930
Corporate Bonds, available for sale
Assets
Investments	89,308		84,588
Municipal bonds, available for sale
Assets
Investments	5,798		5,847
Level 2 | Series A warrants
Liabilities
Warrant liability		$ 43,900
Fair Value Measurements on Recurring Basis
Assets
Total investments	219,759		167,365
Liabilities
Total warrant liability	55,876		6,113
Fair Value Measurements on Recurring Basis | RTI warrants
Liabilities
Warrant liability	3,893		5,175
Fair Value Measurements on Recurring Basis | Private warrants
Liabilities
Warrant liability	733		938
Fair Value Measurements on Recurring Basis | Series A warrants
Liabilities
Warrant liability	51,250		0
Fair Value Measurements on Recurring Basis | Commercial paper, available for sale
Assets
Investments	124,653		76,930
Fair Value Measurements on Recurring Basis | Corporate Bonds, available for sale
Assets
Investments	89,308		84,588
Fair Value Measurements on Recurring Basis | Municipal bonds, available for sale
Assets
Investments	5,798		5,847
Fair Value Measurements on Recurring Basis | Level 1
Assets
Total investments	0		0
Liabilities
Total warrant liability	0		0
Fair Value Measurements on Recurring Basis | Level 1 | RTI warrants
Liabilities
Warrant liability	0		0
Fair Value Measurements on Recurring Basis | Level 1 | Private warrants
Liabilities
Warrant liability	0		0
Fair Value Measurements on Recurring Basis | Level 1 | Series A warrants
Liabilities
Warrant liability	0		0
Fair Value Measurements on Recurring Basis | Level 1 | Commercial paper, available for sale
Assets
Investments	0		0
Fair Value Measurements on Recurring Basis | Level 1 | Corporate Bonds, available for sale
Assets
Investments	0		0
Fair Value Measurements on Recurring Basis | Level 1 | Municipal bonds, available for sale
Assets
Investments	0		0
Fair Value Measurements on Recurring Basis | Level 2
Assets
Total investments	219,759		167,365
Liabilities
Total warrant liability	51,250		0
Fair Value Measurements on Recurring Basis | Level 2 | RTI warrants
Liabilities
Warrant liability	0		0
Fair Value Measurements on Recurring Basis | Level 2 | Private warrants
Liabilities
Warrant liability	0		0
Fair Value Measurements on Recurring Basis | Level 2 | Series A warrants
Liabilities
Warrant liability	51,250		0
Fair Value Measurements on Recurring Basis | Level 2 | Commercial paper, available for sale
Assets
Investments	124,653		76,930
Fair Value Measurements on Recurring Basis | Level 2 | Corporate Bonds, available for sale
Assets
Investments	89,308		84,588
Fair Value Measurements on Recurring Basis | Level 2 | Municipal bonds, available for sale
Assets
Investments	5,798		5,847
Fair Value Measurements on Recurring Basis | Level 3
Assets
Total investments	0		0
Liabilities
Total warrant liability	4,626		6,113
Fair Value Measurements on Recurring Basis | Level 3 | RTI warrants
Liabilities
Warrant liability	3,893		5,175
Fair Value Measurements on Recurring Basis | Level 3 | Private warrants
Liabilities
Warrant liability	733		938
Fair Value Measurements on Recurring Basis | Level 3 | Series A warrants
Liabilities
Warrant liability	0		0
Fair Value Measurements on Recurring Basis | Level 3 | Commercial paper, available for sale
Assets
Investments	0		0
Fair Value Measurements on Recurring Basis | Level 3 | Corporate Bonds, available for sale
Assets
Investments	0		0
Fair Value Measurements on Recurring Basis | Level 3 | Municipal bonds, available for sale
Assets
Investments	$ 0		$ 0

FAIR VALUE OF FINANCIAL INSTR_4

FAIR VALUE OF FINANCIAL INSTRUMENTS - Fair Value Measurement Inputs (Details) - Level 3 - Fair Value Measurements on Recurring Basis	Mar. 31, 2022	Dec. 31, 2021
Expected annual dividend yield | Private warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant, measurement input	0	0
Expected annual dividend yield | RTI warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant, measurement input	0	0
Expected volatility | Private warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant, measurement input	0.7170	0.6950
Expected volatility | RTI warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant, measurement input	0.581	0.596
Risk-free rate of return | Private warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant, measurement input	0.0242	0.0114
Risk-free rate of return | RTI warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant, measurement input	0.0239	0.0097
Expected option term (years) | Private warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant, expected option term (years)	3 years 11 months 19 days	4 years 2 months 19 days
Expected option term (years) | RTI warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant, expected option term (years)	2 years 9 months	3 years

FAIR VALUE OF FINANCIAL INSTR_5

FAIR VALUE OF FINANCIAL INSTRUMENTS - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 17, 2022	Dec. 31, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value change of warrants	$ 5,835,000	$ 13,621,000
RTI warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrants repurchase maximum threshold	15,000,000
Series A warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair value change of warrants	$ 7,300,000
Level 3 | Private warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Dividend yield on warrants	0.00%
Aggregate value	$ 733,000			$ 938,000
Level 3 | RTI warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Dividend yield on warrants	0.00%
Aggregate value	$ 3,893,000			$ 5,175,000
Level 2 | Series A warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Warrants, fair value			$ 43,900,000

FAIR VALUE OF FINANCIAL INSTR_6

FAIR VALUE OF FINANCIAL INSTRUMENTS - Level 3 Liabilities Measured at Fair Value (Details) - Level 3 $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Private warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	$ 938
Change in fair value	(205)
Ending Balance	733
RTI warrants
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning Balance	5,175
Change in fair value	(1,282)
Ending Balance	$ 3,893

AVAILABLE-FOR-SALE INVESTMENT_2

AVAILABLE-FOR-SALE INVESTMENTS - Investments by Major Security Type (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 220,336	$ 167,602
Gross Unrealized Gains	6	0
Gross Unrealized Losses	(583)	(237)
Total Fair Value	219,759	167,365
Commercial Paper
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	124,747	76,961
Gross Unrealized Gains	1	0
Gross Unrealized Losses	(95)	(31)
Total Fair Value	124,653	76,930
Corporate Bonds
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	89,731	84,771
Gross Unrealized Gains	5	0
Gross Unrealized Losses	(428)	(183)
Total Fair Value	89,308	84,588
Municipal Bonds
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	5,858	5,870
Gross Unrealized Gains	0	0
Gross Unrealized Losses	(60)	(23)
Total Fair Value	$ 5,798	$ 5,847

AVAILABLE-FOR-SALE INVESTMENT_3

AVAILABLE-FOR-SALE INVESTMENTS - Investments by Contractual Maturity (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Securities, Available-for-sale, Maturity, Amortized Cost, Rolling Maturity [Abstract]
Due within one year	$ 180,970	$ 117,164
Due after one year through five years	39,366	50,438
Amortized Cost	220,336	167,602
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling Maturity, Fair Value [Abstract]
Due within one year	180,711	117,100
Due after one year through five years	39,048	50,265
Debt securities available for sale	$ 219,759	$ 167,365

AVAILABLE-FOR-SALE INVESTMENT_4

AVAILABLE-FOR-SALE INVESTMENTS - Additional Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Average remaining maturity of available-for-sale securities	6 months
Other-than-temporary impairment losses recognized on available-for-sale securities	$ 0	$ 0

CONTINGENCIES (Details)

CONTINGENCIES (Details)	May 11, 2021classAction
Commitments and Contingencies Disclosure [Abstract]
Number of class actions complaints filed	2

LEASES - Additional Information

LEASES - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jan. 01, 2022	Dec. 31, 2021
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets	$ 13,953	$ 12,300	$ 0
Present value of lease liabilities	$ 14,573	$ 12,700
Real Estate, Equipment and Vehicles
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	11 years
Maximum | Real Estate, Equipment and Vehicles
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	11 years
Minimum | Real Estate, Equipment and Vehicles
Lessee, Lease, Description [Line Items]
Lessee, Operating Lease, Term of Contract	1 year

LEASES - Schedule Of Lease Expe

LEASES - Schedule Of Lease Expense And Supplemental Cash Flow Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Leases [Abstract]
Operating lease cost	$ 423
Short-term lease cost	103
Total lease cost	526
Operating cash flows from operating leases	230
Operating right-of-use liabilities	$ 1,943
Weighted-average remaining lease term (in years) - operating leases	9 years 4 months 24 days
Weighted-average discount rate - operating leases	4.00%

LEASES - Schedule Of Supplement

LEASES - Schedule Of Supplemental Balance Sheet Information Related To Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jan. 01, 2022	Dec. 31, 2021
Leases [Abstract]
Operating lease right-of-use assets	$ 13,953	$ 12,300	$ 0
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued expenses
Accrued expenses	$ 1,012
Other long-term liabilities	13,561		$ 0
Present value of lease liabilities	$ 14,573	$ 12,700

LEASES - Schedule Of Maturities

LEASES - Schedule Of Maturities Of The Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Jan. 01, 2022
Leases [Abstract]
2022 (April through December)	$ 1,119
2023	1,824
2024	1,867
2025	1,918
2026	1,836
2027	1,856
Thereafter	7,391
Total lease payments	17,811
Less: Imputed interest	(3,238)
Present value of lease liabilities	$ 14,573	$ 12,700

Uncategorized Items - pct-20220

Label	Element	Value
Accounting Standards Update [Extensible Enumeration]	us-gaap_AccountingStandardsUpdateExtensibleList	Accounting Standards Update 2020-06 [Member]